

ISSN 1007-9327 (print)
ISSN 2219-2840 (online)



WJG

World Journal of Gastroenterology®

Indexed and Abstracted in:

Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Digital Object Identifier. ISI, Thomson Reuters, 2009 Impact Factor: 2.092 (33/65 Gastroenterology and Hepatology).

Volume 16 Number 47
December 21, 2010

World J Gastroenterol
2010 December 21; 16(47): 5907-6034

Online Submissions

www.wjgnet.com/1007-9327/office
www.wjgnet.com

Printed on Acid-free Paper

世界胃肠病学杂志

Editorial Board

2010-2013

The *World Journal of Gastroenterology* Editorial Board consists of 1144 members, representing a team of worldwide experts in gastroenterology and hepatology. They are from 60 countries, including Albania (1), Argentina (8), Australia (29), Austria (14), Belgium (12), Brazil (10), Brunei Darussalam (1), Bulgaria (2), Canada (20), Chile (3), China (69), Colombia (1), Croatia (2), Cuba (1), Czech (4), Denmark (8), Ecuador (1), Egypt (2), Estonia (2), Finland (8), France (24), Germany (75), Greece (14), Hungary (10), India (26), Iran (6), Ireland (7), Israel (12), Italy (101), Japan (112), Jordan (1), Kuwait (1), Lebanon (3), Lithuania (2), Malaysia (1), Mexico (10), Moldova (1), Netherlands (29), New Zealand (2), Norway (11), Pakistan (2), Poland (11), Portugal (4), Romania (3), Russia (1), Saudi Arabia (3), Serbia (3), Singapore (10), South Africa (2), South Korea (32), Spain (38), Sweden (18), Switzerland (11), Thailand (1), Trinidad and Tobago (1), Turkey (24), United Arab Emirates (2), United Kingdom (82), United States (249), and Uruguay (1).

HONORARY EDITORS-IN-CHIEF

James L Boyer, *New Haven*
Ke-Ji Chen, *Beijing*
Martin H Floch, *New Haven*
Emmet B Keeffe, *Palo Alto*
Geng-Tao Liu, *Beijing*
Lein-Ray Mo, *Tainan*
Eamonn M Quigley, *Cork*
Rafiq A Sheikh, *Sacramento*
Nicholas J Talley, *Rochester*
Ming-Lung Yu, *Kaohsiung*

PRESIDENT AND EDITOR-IN-CHIEF

Lian-Sheng Ma, *Beijing*

ACADEMIC EDITOR-IN-CHIEF

Tauseef Ali, *Oklahoma City*
Mauro Bortolotti, *Bologna*
Tarkan Karakan, *Ankara*
Weekitt Kittisupamongkol, *Bangkok*
Anastasios Koulaouzidis, *Edinburgh*
Bo-Rong Pan, *Xi'an*
Sylvia LF Pender, *Southampton*
Max S Petrov, *Auckland*
George Y Wu, *Farmington*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Peter Draganov, *Florida*
Hugh J Freeman, *Vancouver*
Maria C Gutiérrez-Ruiz, *Mexico*
Kazuhiro Hanazaki, *Kochi*
Akio Inui, *Kagoshima*
Kalpesh Jani, *Baroda*
Javier S Martin, *Punta del Este*

Natalia A Osna, *Omaha*
Wei Tang, *Tokyo*
Alan BR Thomson, *Edmonton*
Harry HX Xia, *Hanover*
Jesus K Yamamoto-Furusho, *Mexico*
Yoshio Yamaoka, *Houston*

ASSOCIATE EDITORS-IN-CHIEF

You-Yong Lu, *Beijing*
John M Luk, *Singapore*
Hiroshi Shimada, *Yokohama*

GUEST EDITORIAL BOARD MEMBERS

Chien-Jen Chen, *Taipei*
Yang-Yuan Chen, *Changhua*
Jen-Hwey Chiu, *Taipei*
Seng-Kee Chuah, *Kaohsiung*
Wan-Long Chuang, *Kaohsiung*
Ming-Chih Hou, *Taipei*
Kevin Cheng-Wen Hsiao, *Taipei*
Po-Shiuan Hsieh, *Taipei*
Tsung-Hui Hu, *Kaohsiung*
Wen-Hsin Huang, *Taichung*
Chao-Hung Hung, *Kaohsiung*
I-Rue Lai, *Taipei*
Teng-Yu Lee, *Taichung*
Ching Chung Lin, *Taipei*
Hui-Kang Liu, *Taipei*
Hon-Yi Shi, *Kaohsiung*
Chih-Chi Wang, *Kaohsiung*
Jin-Town Wang, *Taipei*
Cheng-Shyong Wu, *Chia-Yi*
Jaw-Ching Wu, *Taipei*
Jiunn-Jong Wu, *Tainan*
Ming-Shiang Wu, *Taipei*

Ta-Sen Yeh, *Taoyuan*
Hsu-Heng Yen, *Changhua*
Ming-Whei Yu, *Taipei*

MEMBERS OF THE EDITORIAL BOARD



Albania

Bashkim Resuli, *Tirana*



Argentina

Julio H Carri, *Córdoba*
Eduardo de Santibañes, *Buenos Aires*
Bernardo Frider, *Buenos Aires*
Carlos J Pirola, *Buenos Aires*
Bernabe Matias Quesada, *Buenos Aires*
Silvia Sookoian, *Buenos Aires*
Adriana M Torres, *Rosario*
Maria Ines Vaccaro, *Buenos Aires*



Australia

Leon Anton Adams, *Nedlands*
Richard Anderson, *Victoria*
Minoti V Apte, *New South Wales*
Andrew V Biankin, *Sydney*
Filip Braet, *Sydney*
Christopher Christophi, *Melbourne*
Philip G Dinning, *Koagarah*
Guy D Eslick, *Sydney*
Michael A Fink, *Melbourne*

Robert JL Fraser, *Daw Park*
Jacob George, *Westmead*
Mark D Gorrell, *Sydney*
Alexander G Heriot, *Melbourne*
Michael Horowitz, *Adelaide*
John E Kellow, *Sydney*
William Kemp, *Melbourne*
Finlay A Macrae, *Victoria*
Daniel Markovich, *Brisbane*
Vance Matthews, *Melbourne*
Phillip S Oates, *Perth*
Shan Rajendra, *Tasmania*
Rajvinder Singh, *Elizabeth Vale*
Ross C Smith, *Sydney*
Kevin J Spring, *Brisbane*
Nathan Subramaniam, *Brisbane*
Phil Sutton, *Melbourne*
Cuong D Tran, *North Adelaide*
Debbie Trinder, *Fremantle*
David Ian Watson, *Bedford Park*



Austria

Herwig R Cerwenka, *Graz*
Ashraf Dahaba, *Graz*
Peter Ferenci, *Vienna*
Valentin Fuhrmann, *Vienna*
Alfred Gangl, *Vienna*
Alexander M Hirschl, *Wien*
Kurt Lenz, *Linz*
Dietmar Öfner, *Salzburg*
Markus Peck-Radosavljevic, *Vienna*
Markus Raderer, *Vienna*
Stefan Riss, *Vienna*
Georg Roth, *Vienna*
Michael Trauner, *Graz*
Thomas Wild, *Kapellerfeld*



Belgium

Rudi Beyaert, *Gent*
Benedicte Y De Winter, *Antwerp*
Inge I Depoortere, *Leuven*
Olivier Detry, *Liège*
Philip Meuleman, *Ghent*
Marc Peeters, *De Pintelaan*
Freddy Penninckx, *Leuven*
Jean-Yves L Reginster, *Liège*
Mark De Ridder, *Brussels*
Etienne M Sokal, *Brussels*
Kristin Verbeke, *Leuven*
Eddie Wisse, *Keerbergen*



Brazil

José LF Caboclo, *São José do Rio Preto*
Roberto J Carvalho-Filho, *São Paulo*
Jaime Natan Eisig, *São Paulo*
Andre Castro Lyra, *Salvador*
Marcelo Lima Ribeiro, *Braganca Paulista*
Joao Batista Teixeira Rocha, *Santa Maria*
Heitor Rosa, *Goiania*
Damiao C Moraes Santos, *Rio de Janeiro*
Ana Cristina Simões e Silva, *Belo Horizonte*
Eduardo Garcia Vilela, *Belo Horizonte*



Brunei Darussalam

Vui Heng Chong, *Bandar Seri Begawan*



Bulgaria

Zahariy Krastev, *Sofia*
Mihaela Petrova, *Sofia*



Canada

Alain Bitton, *Montreal*
Michael F Byrne, *Vancouver*
Kris Chadee, *Calgary*
Wangxue Chen, *Ottawa*
Ram Prakash Galwa, *Ottawa*
Philip H Gordon, *Montreal*
Waliul Khan, *Ontario*
Qiang Liu, *Saskatoon*
John K Marshall, *Ontario*
Andrew L Mason, *Alberta*
Kostas Pantopoulos, *Quebec*
Nathalie Perreault, *Sherbrooke*
Baljinder Singh Sallh, *Vancouver*
Eldon Shaffer, *Calgary*
Martin Storr, *Calgary*
Pingchang Yang, *Hamilton*
Eric M Yoshida, *Vancouver*
Claudia Zwingmann, *Montreal*



Chile

Marcelo A Beltran, *La Serena*
Xabier De Aretxabala, *Santiago*
Silvana Zanlungo, *Santiago*



China

Hui-Jie Bian, *Xi'an*
San-Jun Cai, *Shanghai*
Guang-Wen Cao, *Shanghai*
Xiao-Ping Chen, *Wuhan*
Chi-Hin Cho, *Hong Kong*
Zong-Jie Cui, *Beijing*
Jing-Yuan Fang, *Shanghai*
De-Liang Fu, *Shanghai*
Ze-Guang Han, *Shanghai*
Chun-Yi Hao, *Beijing*
Ming-Liang He, *Hong Kong*
Ching-Lung Lai, *Hong Kong*
Simon Law, *Hong Kong*
Yuk-Tong Lee, *Hong Kong*
En-Min Li, *Shantou*
Fei Li, *Beijing*
Yu-Yuan Li, *Guangzhou*
Zhao-Shen Li, *Shanghai*
Xing-Hua Lu, *Beijing*
Yi-Min Mao, *Shanghai*
Qin Su, *Beijing*
Paul Kwong-Hang Tam, *Hong Kong*
Yuk Him Tam, *Hong Kong*
Ren-Xiang Tan, *Nanjing*
Wei-Dong Tong, *Chongqing*
Eric WC Tse, *Hong Kong*

Fu-Sheng Wang, *Beijing*
Xiang-Dong Wang, *Shanghai*
Nathalie Wong, *Hong Kong*
Justin CY Wu, *Hong Kong*
Wen-Rong Xu, *Zhenjiang*
An-Gang Yang, *Xi'an*
Wei-Cheng You, *Beijing*
Chun-Qing Zhang, *Jinan*
Jian-Zhong Zhang, *Beijing*
Xiao-Peng Zhang, *Beijing*
Xuan Zhang, *Beijing*



Colombia

Germán Campuzano-Maya, *Medellín*



Croatia

Tamara Cacev, *Zagreb*
Marko Duvnjak, *Zagreb*



Cuba

Damian C Rodriguez, *Havana*



Czech

Jan Bures, *Hradec Kralove*
Milan Jirsa, *Praha*
Marcela Kopacova, *Hradec Kralove*
Pavel Trunečka, *Prague*



Denmark

Leif Percival Andersen, *Copenhagen*
Asbjørn M Drewes, *Aalborg*
Morten Frisch, *Copenhagen*
Jan Mollenhauer, *Odense*
Morten Hylander Møller, *Holte*
Søren Rafaelsen, *Vejle*
Jorgen Rask-Madsen, *Skodsborg*
Peer Wille-Jørgensen, *Copenhagen*



Ecuador

Fernando E Sempértegui, *Quito*



Egypt

Zeinab Nabil Ahmed, *Cairo*
Hussein M Atta, *El-Minia*



Estonia

Riina Salupere, *Tartu*
Tamara Vorobjova, *Tartu*



Finland

Saila Kauhanen, *Turku*

Thomas Kietzmann, *Oulu*
Kaija-Leena Kolho, *Helsinki*
Jukka-Pekka Mecklin, *Jyväskylä*
Minna Nyström, *Helsinki*
Pauli Antero Puolakkainen, *Turku*
Juhani Sand, *Tampere*
Lea Veijola, *Helsinki*



France

Claire Bonithon-Kopp, *Dijon*
Lionel Bueno, *Toulouse*
Sabine Colnot, *Paris*
Catherine Daniel, *Lille Cedex*
Alexis Desmoulière, *Limoges*
Thabut Dominique, *Paris*
Francoise L Fabiani, *Angers*
Jean-Luc Faucheron, *Grenoble*
Jean Paul Galmiche, *Nantes cedex*
Boris Guiu, *Dijon*
Paul Hofman, *Nice*
Laurent Huwart, *Paris*
Juan Iovanna, *Marseille*
Abdel-Majid Khatib, *Paris*
Philippe Lehours, *Bordeaux*
Flavio Maina, *Marseille*
Patrick Marcellin, *Paris*
Rene Gerolami Santandera, *Marseille*
Annie Schmid-Alliana, *Nice cedex*
Alain L Servin, *Châtenay-Malabry*
Stephane Supiot, *Nantes*
Baumert F Thomas, *Strasbourg*
Jean-Jacques Tuech, *Rouen*
Frank Zerbib, *Bordeaux Cedex*



Germany

Erwin Biecker, *Siegburg*
Hubert Blum, *Freiburg*
Thomas Bock, *Tuebingen*
Dean Bogoevski, *Hamburg*
Elfriede Bollschweiler, *Köln*
Jürgen Borlak, *Hannover*
Christa Buechler, *Regensburg*
Jürgen Büning, *Lübeck*
Elke Cario, *Essen*
Bruno Christ, *Halle/Saale*
Christoph F Dietrich, *Bad Mergentheim*
Ulrich R Fölsch, *Kiel*
Nikolaus Gassler, *Aachen*
Markus Gerhard, *Munich*
Dieter Glebe, *Giessen*
Ralph Graeser, *Freiburg*
Axel M Gressner, *Aachen*
Nils Habbe, *Marburg*
Thilo Hackert, *Heidelberg*
Wolfgang Hagmann, *Heidelberg*
Dirk Haller, *Freising*
Philip D Hard, *Giessen*
Claus Hellerbrand, *Regensburg*
Klaus R Herrlinger, *Stuttgart*
Eberhard Hildt, *Berlin*
Andrea Hille, *Goettingen*
Joerg C Hoffmann, *Berlin*
Philippe N Khalil, *Munich*
Andrej Khandoga, *Munich*
Jorg Kleeff, *Munich*
Ingmar Königsrainer, *Tübingen*
Peter Konturek, *Erlangen*

Stefan Kubicka, *Hannover*
Joachim Labenz, *Siegen*
Michael Linnebacher, *Rostock*
Jutta Elisabeth Lüttges, *Riegelsberg*
Peter Malfertheiner, *Magdeburg*
Oliver Mann, *Hamburg*
Peter N Meier, *Hannover*
Sabine Mihm, *Göttingen*
Klaus Mönkemüller, *Bottrop*
Jonas Mudter, *Erlangen*
Sebastian Mueller, *Heidelberg*
Robert Obermaier, *Freiburg*
Matthias Ocker, *Erlangen*
Stephan Johannes Ott, *Kiel*
Gustav Paumgartner, *Munich*
Christoph Reichel, *Bad Brückenau*
Markus Reiser, *Bochum*
Steffen Rickes, *Magdeburg*
Elke Roeb, *Giessen*
Christian Rust, *Munich*
Hans Scherubl, *Berlin*
Martin K Schilling, *Homburg*
Joerg F Schlaak, *Essen*
Rene Schmidt, *Freiburg*
Andreas G Schreyer, *Regensburg*
Karsten Schulmann, *Bochum*
Henning Schulze-Bergkamen, *Mainz*
Manfred V Singer, *Mannheim*
Jens Standop, *Bonn*
Jurgen M Stein, *Frankfurt*
Ulrike S Stein, *Berlin*
Wolfgang R Stremmel, *Heidelberg*
Harald F Teutsch, *Ulm*
Hans L Tillmann, *Leipzig*
Christian Trautwein, *Aachen*
Joerg Trojan, *Frankfurt*
Arndt Vogel, *Hannover*
Siegfried Wagner, *Deggendorf*
Frank Ulrich Weiss, *Greifswald*
Fritz von Weizsäcker, *Berlin*
Thomas Wex, *Magdeburg*
Stefan Wirth, *Wuppertal*
Marty Zdichavsky, *Tübingen*



Greece

Helen Christopoulou-Aletra, *Thessaloniki*
T Choli-Papadopoulou, *Thessaloniki*
Tsianos Epameinondas, *Ioannina*
Ioannis Kanellos, *Thessaloniki*
Elias A Kouroumalis, *Heraklion*
Ioannis E Koutroubakis, *Heraklion*
Michael Koutsilieris, *Athens*
Andreas Larentzakis, *Athens*
Emanuel K Manesis, *Athens*
Spilios Manolakopoulos, *Athens*
Konstantinos Mimidis, *Alexandroupolis*
George Papatheodoridis, *Athens*
Spiros Sgouros, *Athens*
Evangelos Tsiambas, *Ag Paraskevi Attiki*



Hungary

György M Buzás, *Budapest*
László Czakó, *Szeged*
Gyula Farkas, *Szeged*
Peter Hegyi, *Szeged*
Peter L Lakatos, *Budapest*

Yvette Mándi, *Szeged*
Zoltan Rakonczay, *Szeged*
Ferenc Sipos, *Budapest*
Zsuzsa Szondy, *Debrecen*
Gabor Veres, *Budapest*



India

Philip Abraham, *Mumbai*
Vineet Ahuja, *New Delhi*
Giriraj Ratan Chandak, *Hyderabad*
Devinder Kumar Dhawan, *Chandigarh*
Radha K Dhiman, *Chandigarh*
Pankaj Garg, *Panchkula*
Pramod Kumar Garg, *New Delhi*
Debidas Ghosh, *Midnapore*
Uday C Ghoshal, *Lucknow*
Bhupendra Kumar Jain, *Delhi*
Ashok Kumar, *Lucknow*
Bikash Medhi, *Chandigarh*
Sri P Misra, *Allahabad*
Gopal Nath, *Varanasi*
Samiran Nundy, *New Delhi*
Jagannath Palepu, *Mumbai*
Vandana Panda, *Mumbai*
Benjamin Perakath, *Tamil Nadu*
Ramesh Roop Rai, *Jaipur*
Nageshwar D Reddy, *Hyderabad*
Barjesh Chander Sharma, *New Delhi*
Virendra Singh, *Chandigarh*
Rupjyoti Talukdar, *Guwahati*
Rakesh Kumar Tandon, *New Delhi*
Jai Dev Wig, *Chandigarh*



Iran

Mohammad Abdollahi, *Tehran*
Peyman Adibi, *Isfahan*
Seyed-Moayed Alavian, *Tehran*
Seyed Mohsen Dehghani, *Shiraz*
Reza Malekzadeh, *Tehran*
Alireza Mani, *Tehran*



Ireland

Billy Bourke, *Dublin*
Ted Dinan, *Cork*
Catherine Greene, *Dublin*
Ross McManus, *Dublin*
Anthony P Moran, *Galway*
Marion Rowland, *Dublin*



Israel

Simon Bar-Meir, *Hashomer*
Alexander Becker, *Afula*
Abraham R Eliakim, *Haifa*
Sigal Fishman, *Tel Aviv*
Boris Kirshtein, *Beer Sheva*
Eli Magen, *Ashdod*
Menachem Moshkowitz, *Tel-Aviv*
Assy Nimer, *Safed*
Shmuel Odes, *Beer Sheva*
Mark Pines, *Bet Dagan*
Ron Shaoul, *Haifa*
Ami D Sperber, *Beer-Sheva*



Italy

Donato F Altomare, *Bari*
 Piero Amodio, *Padova*
 Angelo Andriulli, *San Giovanni Rotondo*
 Paolo Angeli, *Padova*
 Bruno Annibale, *Rome*
 Paolo Aurello, *Rome*
 Salvatore Auricchio, *Naples*
 Antonio Basoli, *Rome*
 Claudio Bassi, *Verona*
 Gabrio Bassotti, *Perugia*
 Mauro Bernardi, *Bologna*
 Alberto Biondi, *Rome*
 Luigi Bonavina, *Milano*
 Guglielmo Borgia, *Naples*
 Roberto Berni Canani, *Naples*
 Maria Gabriella Caruso, *Bari*
 Fausto Catena, *Bologna*
 Giuseppe Chiarioni, *Valeggio*
 Michele Cicala, *Rome*
 Dario Conte, *Milano*
 Francesco Costa, *Pisa*
 Antonio Craxi, *Palermo*
 Salvatore Cucchiara, *Rome*
 Giuseppe Currò, *Messina*
 Mario M D'Elios, *Florence*
 Mirko D'Onofrio, *Verona*
 Silvio Danese, *Milano*
 Roberto de Franchis, *Milano*
 Paola De Nardi, *Milan*
 Giovanni D De Palma, *Naples*
 Giuliana Decorti, *Trieste*
 Gianlorenzo Dionigi, *Varese*
 Massimo Falconi, *Verona*
 Silvia Fargion, *Milan*
 Giammarco Fava, *Ancona*
 Francesco Feo, *Sassari*
 Alessandra Ferlini, *Ferrara*
 Alessandro Ferrero, *Torino*
 Mirella Fraquelli, *Milan*
 Luca Frulloni, *Verona*
 Giovanni B Gaeta, *Napoli*
 Antonio Gasbarrini, *Rome*
 Edoardo G Giannini, *Genoa*
 Alessandro Granito, *Bologna*
 Fabio Grizzi, *Milan*
 Salvatore Gruttadauria, *Palermo*
 Pietro Invernizzi, *Milan*
 Achille Iolascon, *Naples*
 Angelo A Izzo, *Naples*
 Ezio Laconi, *Cagliari*
 Giovanni Latella, *L'Aquila*
 Massimo Leverro, *Rome*
 Francesco Luzzza, *Catanzaro*
 Lucia Malaguarnera, *Catania*
 Francesco Manguso, *Napoli*
 Pier Mannuccio Mannucci, *Milan*
 Giancarlo Mansueto, *Verona*
 Giulio Marchesini, *Bologna*
 Mara Massimi, *Coppito*
 Giovanni Milito, *Rome*
 Giuseppe Montalto, *Palermo*
 Giovanni Monteleone, *Rome*
 Luca Morelli, *Trento*
 Giovanni Musso, *Torino*
 Mario Nano, *Torino*
 Gerardo Nardone, *Napoli*
 Riccardo Nascimbeni, *Brescia*
 Valerio Nobili, *Rome*
 Fabio Pace, *Milan*
 Nadia Peparini, *Rome*

Marcello Persico, *Naples*
 Mario Pescatori, *Rome*
 Raffaele Pezzilli, *Bologna*
 Alberto Piperno, *Monza*
 Anna C Piscaglia, *Rome*
 Piero Portincasa, *Bari*
 Michele Reni, *Milan*
 Vittorio Ricci, *Pavia*
 Oliviero Riggio, *Rome*
 Mario Rizzetto, *Torino*
 Ballarin Roberto, *Modena*
 Gerardo Rosati, *Potenza*
 Franco Roviello, *Siena*
 Cesare Ruffolo, *Treviso*
 Massimo Ruggie, *Padova*
 Marco Scarpa, *Padova*
 Carmelo Scarpignato, *Parma*
 Giuseppe Sica, *Rome*
 Marco Silano, *Rome*
 Pierpaolo Sileri, *Rome*
 Vincenzo Stanghellini, *Bologna*
 Fiorucci Stefano, *Perugia*
 Giovanni Tarantino, *Naples*
 Alberto Tommasini, *Trieste*
 Guido Torzilli, *Rozzano Milan*
 Cesare Tosetti, *Porretta Terme*
 Antonello Trecca, *Rome*
 Vincenzo Villanacci, *Brescia*
 Lucia Ricci Vitiani, *Rome*
 Marco Vivarelli, *Bologna*



Japan

Kyoichi Adachi, *Izumo*
 Yasushi Adachi, *Sapporo*
 Takafumi Ando, *Nagoya*
 Akira Andoh, *Otsu*
 Masahiro Arai, *Tokyo*
 Hitoshi Asakura, *Tokyo*
 Kazuo Chijiwa, *Miyazaki*
 Yuichiro Eguchi, *Saga*
 Itaru Endo, *Yokohama*
 Munechika Enjoji, *Fukuoka*
 Yasuhiro Fujino, *Akashi*
 Mitsuhiko Fujishiro, *Tokyo*
 Kouhei Fukushima, *Sendai*
 Masanori Hatakeyama, *Tokyo*
 Keiji Hirata, *Kitakyushu*
 Toru Hiyama, *Higashihiroshima*
 Masahiro Iizuka, *Akita*
 Susumu Ikehara, *Osaka*
 Kenichi Ikejima, *Bunkyo-ku*
 Yutaka Inagaki, *Kanagawa*
 Hiromi Ishibashi, *Nagasaki*
 Shunji Ishihara, *Izumo*
 Toru Ishikawa, *Niigata*
 Toshiyuki Ishiwata, *Tokyo*
 Hajime Isomoto, *Nagasaki*
 Yoshiaki Iwasaki, *Okayama*
 Satoru Kakizaki, *Gunma*
 Terumi Kamisawa, *Tokyo*
 Mototsugu Kato, *Sapporo*
 Naoya Kato, *Tokyo*
 Takumi Kawaguchi, *Kurume*
 Yohei Kida, *Kainan*
 Shogo Kikuchi, *Aichi*
 Tsuneo Kitamura, *Chiba*
 Takashi Kobayashi, *Tokyo*
 Yasuhiro Koga, *Isehara*
 Takashi Kojima, *Sapporo*
 Norihiro Kokudo, *Tokyo*
 Masatoshi Kudo, *Osaka*
 Shin Maeda, *Tokyo*
 Satoshi Mamori, *Hyogo*
 Atsushi Masamune, *Sendai*
 Yasushi Matsuzaki, *Tsukuba*
 Kenji Miki, *Tokyo*
 Toshihiro Mitaka, *Sapporo*
 Hiroto Miwa, *Hyogo*
 Kotaro Miyake, *Tokushima*
 Manabu Morimoto, *Yokohama*
 Yoshiharu Motoo, *Kanazawa*
 Yoshiaki Murakami, *Hiroshima*
 Yoshiki Murakami, *Kyoto*
 Kunihiko Murase, *Tusima*
 Akihito Nagahara, *Tokyo*
 Yuji Naito, *Kyoto*
 Atsushi Nakajima, *Yokohama*
 Hisato Nakajima, *Tokyo*
 Hiroki Nakamura, *Yamaguchi*
 Shotaro Nakamura, *Fukuoka*
 Akimasa Nakao, *Nagoya*
 Shuhei Nishiguchi, *Hyogo*
 Mikio Nishioka, *Niihama*
 Keiji Ogura, *Tokyo*
 Susumu Ohmada, *Maebashi*
 Hirohide Ohnishi, *Akita*
 Kenji Okajima, *Nagoya*
 Kazuichi Okazaki, *Osaka*
 Morikazu Onji, *Ehime*
 Satoshi Osawa, *Hamamatsu*
 Hidetsugu Saito, *Tokyo*
 Yutaka Saito, *Tokyo*
 Naoaki Sakata, *Sendai*
 Yasushi Sano, *Chiba*
 Tokihiko Sawada, *Tochigi*
 Tomohiko Shimatan, *Hiroshima*
 Yukihiko Shimizu, *Kyoto*
 Shinji Shimoda, *Fukuoka*
 Yoshio Shirai, *Niigata*
 Masayuki Sho, *Nara*
 Shoichiro Sumi, *Kyoto*
 Hidekazu Suzuki, *Tokyo*
 Masahiro Tajika, *Nagoya*
 Yoshihisa Takahashi, *Tokyo*
 Toshinari Takamura, *Kanazawa*
 Hiroaki Takeuchi, *Kochi*
 Yoshitaka Takuma, *Okayama*
 Akihiro Tamori, *Osaka*
 Atsushi Tanaka, *Tokyo*
 Shinji Tanaka, *Hiroshima*
 Satoshi Tanno, *Hokkaido*
 Shinji Togo, *Yokohama*
 Hitoshi Tsuda, *Tokyo*
 Hiroyuki Uehara, *Osaka*
 Masahito Uemura, *Kashihara*
 Yoshiyuki Ueno, *Sendai*
 Mitsuyoshi Urashima, *Tokyo*
 Takuya Watanabe, *Niigata*
 Satoshi Yamagiwa, *Niigata*
 Taketo Yamaguchi, *Chiba*
 Mitsunori Yamakawa, *Yamagata*
 Takayuki Yamamoto, *Yokkaichi*
 Yutaka Yata, *Maebashi*
 Hiroshi Yoshida, *Tokyo*
 Norimasa Yoshida, *Kyoto*
 Yuichi Yoshida, *Osaka*
 Kentaro Yoshika, *Toyoake*
 Hitoshi Yoshiji, *Nara*
 Katsutoshi Yoshizato, *Higashihiroshima*
 Tomoharu Yoshizumi, *Fukuoka*



Jordan

Ismail Matalka, *Irbid*

**Kuwait**Islam Khan, *Safat***Lebanon**Bassam N Abboud, *Beirut*
Ala I Sharara, *Beirut*
Rita Slim, *Beirut***Lithuania**Giedrius Barauskas, *Kaunas*
Limas Kupcinskas, *Kaunas***Malaysia**Andrew Seng Boon Chua, *Ipoh***Mexico**Richard A Awad, *Mexico*
Aldo Torre Delgadillo, *Mexico*
Diego Garcia-Compean, *Monterrey*
Paulino M Hernández Magro, *Celaya*
Miguel Angel Mercado, *Distrito Federal*
Arturo Panduro, *Jalisco*
Omar Vergara-Fernandez, *Tlalpan*
Saúl Villa-Trevio, *Mexico***Moldova**Igor Mishin, *Kishinev***Netherlands**Ulrich Beuers, *Amsterdam*
Lee Bouwman, *Leiden*
Albert J Bredenoord, *Nieuwegein*
Lodewijk AA Brosens, *Utrecht*
J Bart A Crusius, *Amsterdam*
Wouter de Herder, *Rotterdam*
Pieter JF de Jonge, *Rotterdam*
Robert J de Knegt, *Rotterdam*
Wendy W Johanna de Leng, *Utrecht*
Annemarie de Vries, *Rotterdam*
James CH Hardwick, *Leiden*
Frank Hoentjen, *Haarlem*
Misha Luyer, *Sittard*
Jeroen Maljaars, *Maastricht*
Gerrit A Meijer, *Amsterdam*
Servaas Morré, *Amsterdam*
Chris JJ Mulder, *Amsterdam*
John Plukker, *Groningen*
Albert Frederik Pull ter Gunne, *Tilburg*
Paul E Sijens, *Groningen*
BW Marcel Spanier, *Arnhem*
Shiri Sverdlov, *Maastricht*
Maarten Tushuizen, *Amsterdam*
Jantine van Baal, *Heidelberglaan*
Astrid van der Velde, *The Hague*
Karel van Erpecum, *Utrecht*
Loes van Keimpema, *Nijmegen*Robert Christiaan Verdonk, *Groningen*
Erwin G Zoetendal, *Wageningen***New Zealand**Andrew S Day, *Christchurch***Norway**Olav Dalgard, *Oslo*
Trond Peder Flaten, *Trondheim*
Reidar Fossmark, *Trondheim*
Rasmus Goll, *Tromsø*
Ole Høie, *Arendal*
Asle W Medhus, *Oslo*
Espen Melum, *Oslo*
Trine Olsen, *Tromsø*
Eyvind J Paulssen, *Tromsø*
Jon Arne Søreide, *Stavanger*
Kjetil Søreide, *Stavanger***Pakistan**Shahab Abid, *Karachi*
Syed MW Jafri, *Karachi***Poland**Marek Bebenek, *Wroclaw*
Tomasz Brzozowski, *Cracow*
Halina Cichoż-Lach, *Lublin*
Andrzej Dabrowski, *Bialystok*
Hanna Gregorek, *Warsaw*
Marek Hartleb, *Katowice*
Beata Jolanta Jabłońska, *Katowice*
Stanislaw J Konturek, *Krakow*
Jan Kulig, *Krakow*
Dariusz M Lebensztejn, *Bialystok*
Julian Swierczynski, *Gdansk***Portugal**Raquel Almeida, *Porto*
Ana Isabel Lopes, *Lisboa Codex*
Ricardo Marcos, *Porto*
Guida Portela-Gomes, *Estoril***Romania**Dan L Dumitrascu, *Cluj*
Adrian Saftoiu, *Craiova*
Andrada Seicean, *Cluj-Napoca***Russia**Vasiliy I Reshetnyak, *Moscow***Saudi Arabia**Ibrahim A Al Mofleh, *Riyadh*
Abdul-Wahed Meshikhes, *Qatif*
Faisal Sanai, *Riyadh***Serbia**Tamara M Alempijevic, *Belgrade*
Dusan M Jovanovic, *Sremska Kamenica*
Zoran Krivokapic, *Belgrade***Singapore**Madhav Bhatia, *Singapore*
Kong Weng Eu, *Singapore*
Brian Kim Poh Goh, *Singapore*
Khek-Yu Ho, *Singapore*
Kok Sun Ho, *Singapore*
Fock Kwong Ming, *Singapore*
London Lucien Ooi, *Singapore*
Nagarajan Perumal, *Singapore*
Francis Seow-Choen, *Singapore***South Africa**Rosemary Joyce Burnett, *Pretoria*
Michael Kew, *Cape Town***South Korea**Sang Hoon Ahn, *Seoul*
Sung-Gil Chi, *Seoul*
Myung-Gyu Choi, *Seoul*
Hoon Jai Chun, *Seoul*
Yeun-Jun Chung, *Seoul*
Young-Hwa Chung, *Seoul*
Kim Donghee, *Seoul*
Ki-Baik Hahm, *Incheon*
Sun Pyo Hong, *Geonggi-do*
Seong Gyu Hwang, *Seongnam*
Hong Joo Kim, *Seoul*
Jae J Kim, *Seoul*
Jin-Hong Kim, *Suwon*
Nayoung Kim, *Seongnam-si*
Sang Geon Kim, *Seoul*
Seon Hahn Kim, *Seoul*
Sung Kim, *Seoul*
Won Ho Kim, *Seoul*
Jeong Min Lee, *Seoul*
Kyu Taek Lee, *Seoul*
Sang Kil Lee, *Seoul*
Sang Yeoup Lee, *Gyeongsangnam-do*
Yong Chan Lee, *Seoul*
Eun-Yi Moon, *Seoul*
Hyoung-Chul Oh, *Seoul*
Seung Woon Paik, *Seoul*
Joong-Won Park, *Goyang*
Ji Kon Ryu, *Seoul*
Si Young Song, *Seoul*
Marie Yeo, *Suwon*
Byung Chul Yoo, *Seoul*
Dae-Yeul Yu, *Daejeon***Spain**Maria-Angeles Aller, *Madrid*
Raul J Andrade, *Málaga*
Luis Aparisi, *Valencia*
Gloria González Aseguinolaza, *Navarra*
Matias A Avila, *Pamplona*

Fernando Azpiroz, *Barcelona*
 Ramon Bataller, *Barcelona*
 Belén Beltrán, *Valencia*
 Adolfo Benages, *Valencia*
 Josep M Bordas, *Barcelona*
 Lisardo Boscá, *Madrid*
 Luis Bujanda, *San Sebastián*
 Juli Busquets, *Barcelona*
 Matilde Bustos, *Pamplona*
 José Julián calvo Andrés, *Salamanca*
 Andres Cardenas, *Barcelona*
 Antoni Castells, *Barcelona*
 Fernando J Corrales, *Pamplona*
 JEDomínguez-Muñoz, *Santiago de Compostela*
 Juan Carlos Laguna Egea, *Barcelona*
 Isabel Fabregat, *Barcelona*
 Antoni Farré, *Barcelona*
 Vicente Felipo, *Valencia*
 Laureano Fernández-Cruz, *Barcelona*
 Luis Grande, *Barcelona*
 Angel Lanas, *Zaragoza*
 Juan-Ramón Larrubia, *Guadalajara*
 María IT López, *Jaén*
 Juan Macías, *Seville*
 Javier Martin, *Granada*
 José Manuel Martin-Villa, *Madrid*
 Julio Mayol, *Madrid*
 Mireia Miquel, *Sabadell*
 Albert Parés, *Barcelona*
 Jesús M Prieto, *Pamplona*
 Pedro L Majano Rodriguez, *Madrid*
 Joan Roselló-Catafau, *Barcelona*
 Eva Vaquero, *Barcelona*



Sweden

Lars Erik Agréus, *Stockholm*
 Mats Andersson, *Stockholm*
 Roland Andersson, *Lund*
 Mauro D'Amato, *Huddinge*
 Evangelos Kalaitzakis, *Gothenburg*
 Greger Lindberg, *Stockholm*
 Annika Lindblom, *Stockholm*
 Sara Lindén, *Göteborg*
 Hanns-Ulrich Marschall, *Stockholm*
 Pär Erik Myreliid, *Linköping*
 Åke Nilsson, *Lund*
 Helena Nordenstedt, *Stockholm*
 Kjell Öberg, *Uppsala*
 Lars A Pahlman, *Uppsala*
 Stefan G Pierzynowski, *Lund*
 Sara Regnér, *Malmö*
 Bobby Tingstedt, *Lund*
 Zongli Zheng, *Stockholm*



Switzerland

Pascal Bucher, *Geneva*
 Michelangelo Foti, *Geneva*
 Jean L Frossard, *Geneva*
 Andreas Geier, *Zürich*
 Pascal Gervaz, *Geneva*
 Gerd A Kullak-Ublick, *Zürich*
 Fabrizio Montecucco, *Geneva*
 Paul M Schneider, *Zürich*
 Felix Stickel, *Berne*
 Bruno Stieger, *Zürich*
 Inti Zlobec, *Basel*



Trinidad and Tobago

Shivananda Nayak, *Mount Hope*



Turkey

Sinan Akay, *Tekirdag*
 Metin Basaranoglu, *Istanbul*
 Yusuf Bayraktar, *Ankara*
 A Mithat Bozdayi, *Ankara*
 Hayrullah Derici, *Balikesir*
 Eren Ersoy, *Ankara*
 Mukaddes Esrefoglu, *Malatya*
 Can Goen, *Kutahya*
 Selin Kapan, *Istanbul*
 Aydin Karabacakoglu, *Konya*
 Cuneyt Kayaalp, *Malatya*
 Kemal Kismet, *Ankara*
 Seyfettin Köklü, *Ankara*
 Mehmet Refik Mas, *Etilik-Ankara*
 Osman C Ozdogan, *Istanbul*
 Bülent Salman, *Ankara*
 Orhan Sezgin, *Mersin*
 Ilker Tasci, *Ankara*
 Müge Tecder-Ünal, *Ankara*
 Ahmet Tekin, *Mersin*
 Mesut Tez, *Ankara*
 Ekmel Tezel, *Ankara*
 Özlem Yilmaz, *Izmir*



United Arab Emirates

Fikri M Abu-Zidan, *Al-Ain*
 Sherif M Karam, *Al-Ain*



United Kingdom

Simon Afford, *Birmingham*
 Navneet K Ahluwalia, *Stockport*
 Mohamed H Ahmed, *Southampton*
 Basil Ammori, *Salford*
 Lesley A Anderson, *Belfast*
 Chin Wee Ang, *Liverpool*
 Yeng S Ang, *Wigan*
 Anthony TR Axon, *Leeds*
 Kathleen B Bamford, *London*
 Jim D Bell, *London*
 John Beynon, *Swansea*
 Chris Briggs, *Sheffield*
 Geoffrey Burnstock, *London*
 Alastair D Burt, *Newcastle*
 Jeff Butterworth, *Shrewsbury*
 Jeremy FL Cobbold, *London*
 Jean E Crabtree, *Leeds*
 Tatjana Crnogorac-Jurcevic, *London*
 William Dickey, *Londonderry*
 Sunil Dolwani, *Cardiff*
 Emad M El-Omar, *Aberdeen*
 A M El-Tawil, *Birmingham*
 Charles B Ferguson, *Belfast*
 Andrew Fowell, *Southampton*
 Piers Gatenby, *London*
 Daniel R Gaya, *Edinburgh*
 Anil George, *London*
 Rob Glynne-Jones, *Northwood*
 Jason CB Goh, *Birmingham*
 Gianpiero Gravante, *Leicester*

Brian Green, *Belfast*
 William Greenhalf, *Liverpool*
 Indra N Guha, *Nottingham*
 Stefan G Hübscher, *Birmingham*
 Robin Hughes, *London*
 Pali Hungin, *Stockton*
 Nawfal Hussein, *Nottingham*
 Clement W Imrie, *Glasgow*
 Janusz AZ Jankowski, *Oxford*
 Sharad Karandikar, *Birmingham*
 Peter Karayiannis, *London*
 Shahid A Khan, *London*
 Patricia F Lalor, *Birmingham*
 John S Leeds, *Sheffield*
 Ian Lindsey, *Oxford*
 Hong-Xiang Liu, *Cambridge*
 Dileep N Lobo, *Nottingham*
 Graham MacKay, *Glasgow*
 Mark Edward McAlindon, *Sheffield*
 Anne McCune, *Bristol*
 Donald Campbell McMillan, *Glasgow*
 Giorgina Mieli-Vergani, *London*
 Jamie Murphy, *London*
 Guy Fairbairn Nash, *Poole*
 James Neuberger, *Birmingham*
 Patrick O'Dwyer, *Glasgow*
 Christos Paraskeva, *Bristol*
 Richard Parker, *North Staffordshire*
 Thamara Perera, *Birmingham*
 Kondragunta Rajendra Prasad, *Leeds*
 D Mark Pritchard, *Liverpool*
 Alberto Quaglia, *London*
 Akhilesh B Reddy, *Cambridge*
 Kevin Robertson, *Glasgow*
 Sanchoy Sarkar, *Liverpool*
 John B Schofield, *Kent*
 Marco Senzolo, *Padova*
 Venkatesh Shanmugam, *Derby*
 Paul Sharp, *London*
 Chew Thean Soon, *Manchester*
 Aravind Suppiah, *East Yorkshire*
 Noriko Suzuki, *Middlesex*
 Simon D Taylor-Robinson, *London*
 Frank I Tovey, *London*
 A McCulloch Veitch, *Wolverhampton*
 Vamsi R Velchuru, *Lowestoft*
 Sumita Verma, *Brighton*
 Catherine Walter, *Cheltenham*
 Julian RF Walters, *London*
 Roger Williams, *London*



United States

Kareem M Abu-Elmagd, *Pittsburgh*
 Sami R Achem, *Florida*
 Golo Ahlenstiel, *Bethesda*
 Bhupinder S Anand, *Houston*
 M Ananthanarayanan, *New York*
 Balamurugan N Appakalal, *Minneapolis*
 Dimitrios V Avgerinos, *New York*
 Shashi Bala, *Worcester*
 Anthony J Bauer, *Pittsburgh*
 Kevin E Behrns, *Gainesville*
 Roberto Bergamaschi, *New York*
 Henry J Binder, *New Haven*
 Edmund J Bini, *New York*
 Wojciech Blonski, *Philadelphia*
 Mark Bloomston, *Columbus*
 Edward L Bradley III, *Sarasota*
 Carla W Brady, *Durham*

David A Brenner, *San Diego*
Adeel A Butt, *Pittsburgh*
Shi-Ying Cai, *New Haven*
Justin MM Cates, *Nashville*
Eugene P Ceppa, *Durham*
Jianyuan Chai, *Long Beach*
Ronald S Chamberlain, *Livingston*
Fei Chen, *Morgantown*
Xian-Ming Chen, *Omaha*
Ramsey Chi-man Cheung, *Palo Alto*
Denesh Chitkara, *East Brunswick*
Clifford S Cho, *Madison*
Parimal Chowdhury, *Arkansas*
John David Christein, *Birmingham*
Thomas Clancy, *Boston*
Ana J Coito, *Los Angeles*
Ricardo Alberto Cruciani, *New York*
Joseph J Cullen, *Iowa City*
Mark J Czaja, *New York*
Mariana D Dabeva, *Bronx*
Jessica A Davila, *Houston*
Conor P Delaney, *Cleveland*
Laurie DeLeve, *Los Angeles*
Anthony J Demetris, *Pittsburgh*
Sharon DeMorrow, *Temple*
Bijan Eghtesad, *Cleveland*
Yoram Elitsur, *Huntington*
Mohamad A Eloubeidi, *Alabama*
Wael El-Rifai, *Nashville*
Sukru H Emre, *New Haven*
Giamila Fantuzzi, *Chicago*
Ashkan Farhadi, *Irvine*
Ronnie Fass, *Tucson*
Martín E Fernández-Zapico, *Rochester*
Alessandro Fichera, *Chicago*
Josef E Fischer, *Boston*
Piero Marco Fisichella, *Maywood*
Fritz Francois, *New York*
Glenn T Furuta, *Aurora*
T Clark Gamblin, *Pittsburgh*
Henning Gerke, *Iowa City*
Jean-Francois Geschwind, *Baltimore*
R Mark Ghobrial, *Texas*
John F Gibbs, *Buffalo*
Shannon S Glaser, *Temple*
Ajay Goel, *Dallas*
Jon C Gould, *Madison*
Eileen F Grady, *San Francisco*
James H Grendell, *New York*
John R Grider, *Richmond*
Anna S Gukovskaya, *Los Angeles*
Chakshu Gupta, *St. Joseph*
Grigoriy E Gurvits, *New York*
Hai-Yong Han, *Phoenix*
Yuan-Ping Han, *Los Angeles*
Imran Hassan, *Springfield*
Charles P Heise, *Madison*
Lisa J Herrinton, *Oakland*
Oscar Joe Hines, *Los Angeles*
Samuel B Ho, *San Diego*
Steven Hochwald, *Gainesville*
Richard Hu, *Los Angeles*
Eric S Hungness, *Chicago*
Jamal A Ibdah, *Columbia*
Atif Iqbal, *Omaha*
Hartmut Jaeschke, *Tucson*
Donald M Jensen, *Chicago*
Robert Jensen, *Bethesda*
Leonard R Johnson, *Memphis*
Andreas M Kaiser, *Los Angeles*
JingXuan Kang, *Charlestown*
John Y Kao, *Michigan*
Randeep Singh Kashyap, *New York*
Rashmi Kaul, *Tulsa*
Jonathan D Kaunitz, *Los Angeles*
Stephen M Kavic, *Baltimore*
Ali Keshavarzian, *Chicago*
Amir Maqbul Khan, *Marshall*
Kusum K Kharbanda, *Omaha*
Chang Kim, *West Lafayette*
Dean Y Kim, *Detroit*
Miran Kim, *Providence*
Burton I Korelitz, *New York*
Josh Korzenik, *Boston*
Richard A Kozarek, *Seattle*
Alyssa M Krasinskas, *Pittsburgh*
Shiu-Ming Kuo, *Buffalo*
Michelle Lai, *Boston*
Michael Leitman, *New York*
Dong-Hui Li, *Houston*
Ming Li, *New Orleans*
Zhiping Li, *Baltimore*
Gary R Lichtenstein, *Philadelphia*
Chen Liu, *Gainesville*
Zhang-Xu Liu, *Los Angeles*
Craig D Logsdon, *Houston*
Kaye M Reid Lombardo, *Rochester*
Michael R Lucey, *Madison*
Kirk Ludwig, *Wisconsin*
James D Luketich, *Pittsburgh*
Patrick M Lynch, *Houston*
John S Macdonald, *New York*
Willis C Maddrey, *Dallas*
Mercedes Susan Mandell, *Aurora*
Christopher Mantyh, *Durham*
Wendy M Mars, *Pittsburgh*
John Marshall, *Columbia*
Robert CG Martin, *Louisville*
Laura E Matarese, *Pittsburgh*
Craig J McClain, *Louisville*
Lynne V McFarland, *Washington*
David J McGee, *Shreveport*
Valentina Medici, *Sacramento*
Stephan Menne, *New York*
Didier Merlin, *Atlanta*
George Michalopoulos, *Pittsburgh*
James M Millis, *Chicago*
Pramod K Mistry, *New Haven*
Emiko Mizoguchi, *Boston*
Huanbiao Mo, *Denton*
Robert C Moesinger, *Ogden*
Smruti R Mohanty, *Chicago*
John Morton, *Stanford*
Peter L Moses, *Burlington*
Sandeep Mukherjee, *Omaha*
Million Mulugeta, *Los Angeles*
Michel M Murr, *Tampa*
Pete Muscarella, *Columbus*
Ece A Mutlu, *Chicago*
Masaki Nagaya, *Boston*
Laura E Nagy, *Cleveland*
Aejaz Nasir, *Tampa*
Udayakumar Navaneethan, *Cincinnati*
Stephen JD O'Keefe, *Pittsburgh*
Robert D Odze, *Boston*
Giuseppe Orlando, *Winston Salem*
Pal Pacher, *Rockville*
Georgios Papachristou, *Pittsburgh*
Jong Park, *Tampa*
William R Parker, *Durham*
Mansour A Parsi, *Cleveland*
Marco Giuseppe Patti, *Chicago*
Zhiheng Pei, *New York*
CS Pitchumoni, *New Brunswick*
Parviz M Pour, *Omaha*
Xiaofa Qin, *Newark*
Florenca Georgina Que, *Rochester*
Massimo Raimondo, *Jacksonville*
Raymund R Razonable, *Minnesota*
Kevin Michael Reavis, *Orange*
Robert V Rege, *Dallas*
Douglas K Rex, *Indianapolis*
Victor E Reyes, *Galveston*
Basil Rigas, *New York*
Richard A Rippe, *Chapel Hill*
Alexander S Rosemurgy, *Tampa*
Philip Rosenthal, *San Francisco*
Raul J Rosenthal, *Weston*
Joel H Rubenstein, *Ann Arbor*
Shawn D Safford, *Norfolk*
Rabih M Salloum, *Rochester*
Bruce E Sands, *Boston*
Tor C Savidge, *Galveston*
Michael L Schilsky, *New Haven*
Beat Schnüriger, *California*
Robert E Schoen, *Pittsburgh*
Matthew James Schuchert, *Pittsburgh*
Ekihiro Seki, *La Jolla*
Le Shen, *Chicago*
Perry Shen, *Winston-Salem*
Stuart Sherman, *Indianapolis*
Mitchell L Shiffman, *Richmond*
Shivendra Shukla, *Columbia*
Bronislaw L Slomiany, *Newark*
Scott Steele, *Fort Lewis*
Branko Stefanovic, *Tallahassee*
Lygia Stewart, *San Francisco*
Luca Stocchi, *Cleveland*
Daniel S Straus, *Riverside*
Robert Todd Striker, *Madison*
Jonathan Strosberg, *Tampa*
Christina Surawicz, *Seattle*
Patricia Sylla, *Boston*
Wing-Kin Syn, *Durham*
Yvette Taché, *Los Angeles*
Kazuaki Takabe, *Richmond*
Kam-Meng Tchou-Wong, *New York*
Klaus Thaler, *Columbia*
Charles Thomas, *Oregon*
Natalie J Torok, *Sacramento*
George Triadafilopoulos, *Stanford*
Chung-Jyi Tsai, *Lexington*
Thérèse Tuohy, *Salt Lake City*
Andrew Ukleja, *Florida*
Santhi Swaroop Vege, *Rochester*
Aaron Vinik, *Norfolk*
Dinesh Vyas, *Washington*
Arnold Wald, *Wisconsin*
Scott A Waldman, *Philadelphia*
Jack R Wands, *Providence*
Jiping Wang, *Boston*
Irving Waxman, *Chicago*
Wilfred M Weinstein, *Los Angeles*
Steven D Wexner, *Weston*
John W Wiley, *Ann Arbor*
Jackie Wood, *Ohio*
Jian Wu, *Sacramento*
Wen Xie, *Pittsburgh*
Guang-Yin Xu, *Galveston*
Fang Yan, *Nashville*
Radha Krishna Yellapu, *New York*
Anthony T Yeung, *Philadelphia*
Zobair M Younossi, *Virginia*
Liqing Yu, *Winston-Salem*
Run Yu, *Los Angeles*
Ruben Zamora, *Pittsburgh*
Michael E Zenilman, *New York*
Mark A Zern, *Sacramento*
Lin Zhang, *Pittsburgh*
Martin D Zielinski, *Rochester*
Michael A Zimmerman, *Colorado*

Contents

Weekly Volume 16 Number 47 December 21, 2010

EDITORIAL

- 5907 Reverse cholesterol transport revisited
van der Velde AE

TOPIC HIGHLIGHT

- 5908 Reverse cholesterol transport: From classical view to new insights
van der Velde AE
- 5916 Scavenger receptor BI: A multi-purpose player in cholesterol and steroid metabolism
Hoekstra M, Van Berkel TJC, Van Eck M
- 5925 Ecto-F₁-ATPase: A moonlighting protein complex and an unexpected apoA-I receptor
Vantourout P, Radojkovic C, Lichtenstein L, Pons V, Champagne E, Martinez LO
- 5936 Biliary cholesterol secretion: More than a simple ABC
Dijkers A, Tietge UJF
- 5946 A new framework for reverse cholesterol transport: Non-biliary contributions to reverse cholesterol transport
Temel RE, Brown JM
- 5953 From blood to gut: Direct secretion of cholesterol *via* transintestinal cholesterol efflux
Vrins CLJ
- 5958 Thyroid hormones and thyroid hormone receptors: Effects of thyromimetics on reverse cholesterol transport
Pedrelli M, Pramfalk C, Parini P

ORIGINAL ARTICLE

- 5965 Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients
Tsouma A, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, Skondra M, Pissimissis N, Tzonou A, Koutsilieris M

- 5975 Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma

Huang JX, Xiao W, Chen WC, Lin MS, Song ZX, Chen P, Zhang YL, Li FY, Qian RY, Salminen E

BRIEF ARTICLE

- 5982 Benefit of combination β -blocker and endoscopic treatment to prevent variceal rebleeding: A meta-analysis

Funakoshi N, Ségalas-Largey F, Duny Y, Oberti F, Valats JC, Bismuth M, Daurès JP, Blanc P

- 5993 Hepatocellular carcinoma treated with transarterial chemoembolization: Dynamic perfusion-CT in the assessment of residual tumor

Ippolito D, Bonaffini PA, Ratti L, Antolini L, Corso R, Fazio F, Sironi S

- 6001 Immune phenotype in children with therapy-naïve remitted and relapsed Crohn's disease

Cseh A, Vasarhelyi B, Molnar K, Szalay B, Svec P, Treszl A, Dezsofi A, Lakatos PL, Arato A, Tulassay T, Veres G

- 6010 Gastroesophageal flap valve status distinguishes clinical phenotypes of large hiatal hernia

Kaneyama H, Kaise M, Arakawa H, Arai Y, Kanazawa K, Tajiri H

- 6016 Diagnosis and surgical treatment of primary hepatic lymphoma

Yang XW, Tan WF, Yu WL, Shi S, Wang Y, Zhang YL, Zhang YJ, Wu MC

- 6020 Meta-analysis of ADH1B and ALDH2 polymorphisms and esophageal cancer risk in China

Zhang GH, Mai RQ, Huang B

- 6026 Prognostic values of chromosome 18q microsatellite alterations in stage II colonic carcinoma

Wang W, Wang GQ, Sun XW, Chen G, Li YF, Zhang LY, Qiu HB, Huang CY, Zhan YQ, Zhou ZW

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Gastroenterology*

APPENDIX I Meetings
I-VI Instructions to authors

AIM AND SCOPE *World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, DOI: 10.3748) is a weekly, open-access, peer-reviewed journal supported by an editorial board of 1144 experts in gastroenterology and hepatology from 60 countries.

The major task of *WJG* is to report rapidly the most recent results in basic and clinical research on esophageal, gastrointestinal, liver, pancreas and biliary tract diseases, *Helicobacter pylori*, endoscopy and gastrointestinal surgery, including: gastroesophageal reflux disease, gastrointestinal bleeding, infection and tumors; gastric and duodenal disorders; intestinal inflammation, microflora and immunity; celiac disease, dyspepsia and nutrition; viral hepatitis, portal hypertension, liver fibrosis, liver cirrhosis, liver transplantation, and metabolic liver disease; molecular and cell biology; geriatric and pediatric gastroenterology; diagnosis and screening, imaging and advanced technology.

FLYLEAF I-VII Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiao-Fang Liu*
Responsible Electronic Editor: *Xiao-Mei Zheng*
Responsible Science Editor: *Lin Tian*
Proofing Editorial Office Director: *Jian-Xia Cheng*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

NAME OF JOURNAL
World Journal of Gastroenterology

LAUNCH DATE
October 1, 1995

RESPONSIBLE INSTITUTION
Department of Science and Technology of Shanxi Province

SPONSOR
Taiyuan Research and Treatment Center for Digestive Diseases, 77 Shuangta Xijie, Taiyuan 030001, Shanxi Province, China

EDITING
Editorial Board of *World Journal of Gastroenterology*, Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-5908-0039
Fax: +86-10-8538-1893
E-mail: wjg@wjgnet.com
<http://www.wjgnet.com>

PUBLISHING
Baishideng Publishing Group Co., Limited, Room 1701, 17/F, Henan Building, No.90 Jaffe Road, Wanchai, Hong Kong, China
Fax: +852-3115-8812
Telephone: +852-5804-2046
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

SUBSCRIPTION
Beijing Baishideng BioMed Scientific Co., Ltd., Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-8538-1892
Fax: +86-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

PRINT SUBSCRIPTION
RMB 245 Yuan for each issue, RMB 11760 Yuan for one year.

ONLINE SUBSCRIPTION
One-Year Price 864.00 USD

PUBLICATION DATE
December 21, 2010

CSSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

HONORARY EDITORS-IN-CHIEF
James L. Boyer, *New Haven*
Ke-Ji Chen, *Beijing*
Martin H Floch, *New Haven*
Geng-Tao Liu, *Beijing*
Emmet B Keefe, *Palo Alto*
Lein-Ray Mo, *Tainan*
Eamonn M Quigley, *Cork*
Rafiq A Sheikh, *Sacramento*
Nicholas J Talley, *Rochester*
Ming-Lung Yu, *Kaohsiung*

PRESIDENT AND EDITOR-IN-CHIEF
Lian-Sheng Ma, *Beijing*

ACADEMIC EDITOR-IN-CHIEF
Tauseef Ali, *Oklahoma*
Mauro Bortolotti, *Bologna*
Tarkan Karakan, *Ankara*
Weekitt Kittisupamongkol, *Bangkok*
Anastasios Koulaouzidis, *Edinburgh*
Gerd A Kullak-Ublick, *Zürich*
Bo-Rong Pan, *Xi'an*
Sylvia LF Pender, *Southampton*
Max S Petrov, *Auckland*
George Y Wu, *Farmington*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF
Peter Draganov, *Florida*
Hugh J Freeman, *Vancouver*
María Concepción Gutiérrez-Ruiz, *México*
Kazuhiro Hanazaki, *Kochi*

Akio Inui, *Kagoshima*
Kalpesh Jani, *Baroda*
Javier S Martin, *Punta del Este*
Natalia A Osna, *Omaha*
Wei Tang, *Tokyo*
Alan BR Thomson, *Edmonton*
Harry HX Xia, *Hanover*

ASSOCIATE EDITORS-IN-CHIEF
You-Yong Lu, *Beijing*
John M Luk, *Pokfulam*
Hiroshi Shimada, *Yokohama*

EDITORIAL OFFICE
Jian-Xia Cheng, Director
World Journal of Gastroenterology
Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-5908-0039
Fax: +86-10-8538-1893
E-mail: wjg@wjgnet.com
<http://www.wjgnet.com>

COPYRIGHT
© 2010 Baishideng. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of Baishideng. Authors are required to grant *World Journal of Gastroenterology* an exclusive license to publish.

SPECIAL STATEMENT
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/1007-9327/g_info_20100315215714.htm. If you do not have web access please contact the editorial office.

ONLINE SUBMISSION
<http://www.wjgnet.com/1007-9327office>

Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients

Aikaterini Tsouma, Chrysanthi Aggeli, Panagiotis Lembessis, George N Zografos, Dimitris P Korkolis, Dimitrios Pectasides, Maria Skondra, Nikolaos Pissimissis, Anastasia Tzonou, Michael Koutsilieris

Aikaterini Tsouma, Chrysanthi Aggeli, Maria Skondra, Nikolaos Pissimissis, Michael Koutsilieris, Department of Experimental Physiology, Medical School, National and Kapodistrian University of Athens, 11527, Athens, Greece

Chrysanthi Aggeli, George N Zografos, Third Department of Surgery, Athens General Hospital "G. Gennimatas", 11527, Athens, Greece

Chrysanthi Aggeli, Dimitris P Korkolis, Department of Surgical Oncology, Hellenic Anticancer Institute, "Saint Savvas" Hospital, 11522, Athens, Greece

Panagiotis Lembessis, Endo/OncoResearch Medical Center, Platia Mavilis, Ampelokipi, 11521, Athens, Greece

Dimitrios Pectasides, Maria Skondra, Second Department of Internal Medicine, Propaedeutic Oncology Section, University of Athens, Attikon University Hospital, 12462, Athens, Greece

Anastasia Tzonou, Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527, Athens, Greece

Author contributions: Tsouma A, Aggeli C, Lembessis P and Koutsilieris M developed the concept of the multiplex PCR-based technique, performed data analysis and wrote the present manuscript; Aggeli C, Zografos GN, Korkolis DP, Pectasides D, Skondra M and Pissimissis N collected blood samples and clinical data, evaluated the clinical data, performed data analysis and participated in the writing of the manuscript; Tzonou A performed statistical analysis and participated in the writing of the manuscript.

Supported by The Ministry of Development of the Greek Government (GGET-AKMON)

Correspondence to: Michael Koutsilieris, MD, PhD, Professor and Chairman, Department of Experimental Physiology, Medical School, National and Kapodistrian University of Athens, Micras Asias 75, Goudi-Athens, 11527, Athens, Greece. mkoutsil@med.uoa.gr

Telephone: +30-210-7462597 Fax: +30-210-7462571

Received: May 17, 2010 Revised: July 12, 2010

Accepted: July 19, 2010

Published online: December 21, 2010

culating tumor cells in the peripheral blood of colorectal cancer (CRC) patients.

METHODS: Peripheral blood samples were collected from 88 CRC patients and 40 healthy individuals from the blood donors' clinic and subsequently analyzed by multiplex RT-PCR for the expression of carcinoembryonic antigen (CEA), cytokeratin 20 (CK20) and epidermal growth factor receptor (EGFR) mRNA. The analysis involved determining the detection rates of CEA, CK20 and EGFR transcripts vs disease stage and overall survival. Median follow-up period was 19 mo (range 8-28 mo).

RESULTS: Rates of CEA, CK20 and EGFR detection in CRC patients were 95.5%, 78.4% and 19.3%, respectively. CEA transcripts were detected in 3 healthy volunteer samples (7.5%), whereas all control samples were tested negative for CK20 and EGFR transcripts. The increasing number of positive detections for CEA, CK20 and EGFR transcripts in each blood sample was positively correlated with Astler-Coller disease stage ($P < 0.001$) and preoperative serum levels of CEA ($P = 0.029$) in CRC patients. Data analysis using Kaplan-Meier estimator documented significant differences in the overall survival of the different CRC patient groups as formed according to the increasing number of positivity for CEA, CK20 and EGFR transcripts.

CONCLUSION: These data suggest that multiplex RT-PCR assay can provide useful information concerning disease stage and overall survival of CRC patients.

© 2010 Baishideng. All rights reserved.

Key words: Peripheral blood; Carcinoembryonic antigen; Cytokeratin 20; Epidermal growth factor receptor; Multiplex reverse transcription polymerase chain reaction

Peer reviewers: Dr. John B Schofield, MB, BS, MRCP, FRCP, Department of Cellular Pathology, Preston Hall, Maidstone,

Abstract

AIM: To develop a multiplex reverse transcription polymerase chain reaction (RT-PCR) method detecting cir-

Kent, ME20 7NH, United Kingdom; Yoshihisa Takahashi, MD, Department of Pathology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan

Tsouma A, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, Skondra M, Pissimissis N, Tzonou A, Koutsilieris M. Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. *World J Gastroenterol* 2010; 16(47): 5965-5974 Available from: URL: <http://www.wjg-net.com/1007-9327/full/v16/i47/5965.htm> DOI: <http://dx.doi.org/10.3748/wjg.v16.i47.5965>

INTRODUCTION

Colorectal cancer (CRC) is one of the most common malignancies in the Western world. In Europe, CRC is the second most frequent cause of death from cancer, after lung cancer^[1]. Although surgical resection followed by chemotherapy is the leading treatment option, approximately half of the patients eventually die due to distant metastases^[2]. Overall survival is associated with the disease stage at the time of diagnosis, suggesting that early detection of disseminated disease may be of great significance^[3]. Consequently, the development of new diagnostic methods that allow better definition of disease stage and better monitoring of disease progression is critical.

In the past years, various techniques have been used for the detection of circulating tumor cells (CTCs) derived from solid tumors in different body compartments, with variable results concerning their accuracy and clinical significance. Reverse transcription polymerase chain reaction (RT-PCR)-based methods have allowed the detection of CTCs in peripheral blood samples, which is characterized by great sensitivity compared to protein-based tumor marker estimations in serum^[4]. However, controversial data have been reported, mainly associated with the choice of molecular tumor markers, cohort size and patient characteristics, as well as false-positive and false-negative results, caused by different PCR conditions and different sets of primers employed by different laboratories.

Among several molecular markers, cytokeratin 20 (CK20), carcinoembryonic antigen (CEA) and epidermal growth factor receptor (EGFR) are those more frequently used for CTC detection in CRC^[5-7]. CK20 is a member of the intermediate filament protein family and a prominent component of the intestinal epithelium. CK20 expression is confined to gastrointestinal epithelium, urothelium, and Merkel cells of the epidermis, as well as malignancies that originate from the aforementioned sites^[8-10]. Serum levels of CEA are commonly used in clinical practice for patient monitoring^[11-14]. In addition, CEA and CK20 mRNA detection using RT-PCR methods have been widely investigated for the detection of CTCs in CRC patients^[15-22]. Furthermore, EGFR has been suggested as a marker that is seldom expressed in hematopoietic cells^[23-25], thus detection of EGFR over-expression in CRC patients has been correlated with the advanced clinical stages and disease progression in CRC patients^[26-30].

The aim of the present study was to establish a multiplex PCR assay targeting the detection of CEA, CK20 and EGFR mRNAs in a single PCR reaction and to evaluate its possible clinical use in CRC patients.

MATERIALS AND METHODS

Subjects

Eighty eight patients (56 males and 32 females) with biopsy-proven primary CRC were enrolled in the study between June 2007 and June 2009. All patients underwent surgical resection for the primary tumor at the "Saint Savvas" Anticancer Hospital, the "G. Gennimatas" Athens General Hospital and the "Attikon" University Hospital, Athens, Greece. The mean age was 69 years (range 43-88 years). Peripheral blood samples were also collected from 40 healthy volunteers (20 men and 20 women), which were used as negative controls. Informed consent was obtained from all patients and healthy volunteers. The study was approved by the local Ethics Committee and conformed to the ethical standards of the Helsinki Declaration.

Cell lines and tissue samples

HT-29 CRC cells are known to express the 3 molecular markers used in our experiments and have been used in spiking experiments for the definition of the sensitivity of the assay^[16,31-37]. HT-29 cells were maintained in Dulbecco's modified Eagle's medium/F-12 (Cambrex, Walkerville, MD, USA), supplemented with 10% heat-inactivated fetal bovine serum (Biochrom, Berlin, Germany) and 100 U/mL penicillin/streptomycin (Cambrex), at 37°C in a humidified atmosphere of 5% CO₂.

CRC and matched normal adjacent tissue samples were obtained from 3 CRC patients during surgery, with the aim of confirming the expression of CEA, CK20 and EGFR mRNA in CRC specimens. The samples were collected in RNAlater solution (Ambion, Austin, TX) and subsequently homogenized (Ultra-Turrax T25; Thermo Fisher Scientific, Cheshire, UK) in 1 mL Tri Reagent TR-118 (MRC Inc. Cincinnati, OH, USA) at 500 g.

Blood sample preparation and RNA extraction

Three milliliters peripheral blood samples were taken preoperatively using a venous catheter into 3 mL EDTA-containing vacutainers (2 samples were obtained from each patient). All blood samples were processed within 4 h of collection. Each blood sample was added to 7.5 mL of Erythrocyte Lysis Buffer (ELB) (containing 155 mmol/L NH₄Cl, 10 mmol/L KHCO₃ and 0.1 mmol/L EDTA pH 7.4) and kept on ice for 45 min with occasional mixing by inversion every 5 min, so as to allow erythrocyte lysis. The samples were then centrifuged at 400 g for 10 min at 4°C and the supernatant was discarded. The pellet of nuclear blood cells was resuspended in 5 mL of ELB and kept on ice for an additional 5 min period in order to remove the remaining red blood cells. Next, the pellet was centrifuged at 400 g for 10 min at 4°C. The pellet was then homog-

Table 1 Primer sequences used for reverse transcription polymerase chain reaction amplification of target transcripts

Tumor marker	Sense	Antisense	PCR product size (bp)	Ref.
CEA	5'-GGGCCACTGTGGCATCATGATTG-3'	5'-TGTAGCTGTTGCAAATGCTTTAAGGAAGAAGC-3'	131	[38]
CK20	5'-CAGACACACGGTGAACATATGG-3'	5'-GATCAGCTTCCACTGTTAGACG-3'	371	[39]
EGFR	5'-TCTCAGCAACATGTCGATGG-3'	5'-TCGCACTTCTTACACTTGCG-3'	474	[40]

CEA: Carcinoembryonic antigen; CK20: Cytokeratin 20; EGFR: Epidermal growth factor receptor; PCR: Polymerase chain reaction.

enized in 1 mL Tri Reagent TR-118 (MRC Inc. Cincinnati, OH, USA) using a 5 mL syringe. Total cellular RNA was extracted using Tri Reagent TR-118, according to manufacturer instructions. The RNA pellet was diluted in diethylpyrocarbonate treated water; total RNA concentration and purity were determined by UV spectrophotometry (Biospec-nano, Shimadzu Biotech, Kyoto, Japan) and its quality was confirmed by amplification of cDNA for β -actin housekeeping gene.

RT-PCR

cDNA was synthesized using Moloney murine leukemia virus (M-MuLV) reverse transcriptase RNase H⁻ (Finnzymes, Oy, Finland). Briefly, a mixture containing 1 μ g of total RNA, 0.5 μ g (25 μ g/mL) oligo-dT₍₁₈₎ primer (Fermentas) and nuclease free water in a total volume of 15 μ L was heated at 70°C for 5 min and then chilled in ice for another 5 min. The mixture was supplemented with 0.5 mmol/L deoxynucleotides (HT Biotechnology LTD), reverse transcriptase buffer containing 50 mmol/L Tris-HCl (pH 8.3), 75 mmol/L KCl, 3 mmol/L MgCl₂, and 10 mmol/L DTT, 40 U Human Placental RNase inhibitor (HT Biotechnology LTD) and finally 200 U M-MuLV reverse transcriptase up to a final volume of 20 μ L; it was subsequently incubated at 37°C for 60 min. Table 1 presents the exact sets of primers used in our study. The sensitivity of the assay was determined in spiking experiments using serial dilutions of HT-29 CRC cells; 10⁵, 10⁴, 10³, 10², 10, 1 and 0 cancer cells were added to different corresponding tubes, each containing 3 mL of blood taken from the same healthy subject. Spiking experiments were followed by erythrocyte lysis and RNA extraction, as described above.

PCR conditions

Primer pairs were chosen so that the sequences were located at different exons and their specificity was confirmed using NCBI Blast (Table 1). PCR reaction was performed using *Taq* DNA Polymerase (Qiagen, Hilden, Germany) in a final reaction volume of 25 μ L containing 1 \times CorallLoad PCR Buffer (contains 15 mmol/L MgCl₂), 1.67 mmol/L MgCl₂ (final concentration), 200 μ mol/L each dNTP and 2.5 U *Taq* DNA Polymerase; cDNA volume and primer concentrations varied depending on the marker and the sample examined. For the amplification of tissue sample cDNAs, primer concentrations and cDNA volumes were 0.4 μ mol/L and 2 μ L, respectively for all markers, while cycling conditions were 94°C for 3 min; 94°C for 1 min, 52°C for 1 min, 72°C for 1 min (36

cycles); 72°C for 10 min for CEA and CK20 cDNA amplifications then 94°C for 3 min; 94°C for 1 min, 57°C for 1 min, 72°C for 1 min (35 cycles); 72°C for 10 min for the amplification of EGFR cDNA. The concentrations and the cycling conditions concerning PCR reactions in serial dilutions of HT-29 cells for each marker were as follows: for the amplification of CEA cDNA, 0.08 μ mol/L of primers and 1 μ L of cDNA were used, while the cycling conditions were 94°C for 3 min, 94°C for 30 s, 58°C for 20 s, 72°C for 30 s (40 cycles); 72°C for 2 min; similarly, CK20 cDNA was amplified using 0.35 μ mol/L of primers and 1 μ L of cDNA, and PCR cycling conditions were 94°C for 3 min; 94°C for 30 s, 58°C for 20 s, 72°C for 30 s (36 cycles); 72°C for 2 min; finally, the primer concentration used for EGFR assays was 0.4 μ mol/L and 2 μ L of cDNA added to the PCR mix, while amplification took place at 94°C for 3 min; 94°C for 1 min, 50°C for 1 min, 72°C for 1 min (39 cycles); 72°C for 10 min. For the multiplex PCR reactions 2 μ L of cDNA were used, adding primer concentrations as follows: CEA 0.06 μ mol/L, CK20 0.15 μ mol/L and EGFR 0.5 μ mol/L. Cycling conditions were 94°C for 15 min; 94°C for 30 s, 58°C for 20 s, 72°C for 30 s (37 cycles); 72°C for 10 min. PCR products were analyzed by electrophoresis on a 2% agarose gel followed by ethidium bromide staining and then captured under ultraviolet light in a Kodak EDAS 290 imaging system (Carestream Health, Rochester, NY, USA).

Statistical analysis

Statistical analysis was performed using the Statistical Package for the Social Sciences Predictive Analytics Software (SPSS PASW Statistics ver. 18.0) (SPSS Inc., Chicago, IL). The potential correlation between the molecular marker expression and the clinical and pathological characteristics of the patients was tested by Spearman's correlation. The overall survival rates were calculated using the Kaplan-Meier estimator and comparisons of survival curves between patient groups were carried out by the log-rank test. Overall survival was defined as the intermediate time interval between sampling and either death or last follow-up. To assess the independent prognostic significance of factors on overall survival, analysis was performed using the Cox proportional hazards regression analysis. A *P* value < 0.05 was considered to be statistically significant.

RESULTS

After CEA, CK20 and EGFR mRNA expression was




Figure 1 Detection of carcinoembryonic antigen, cytokeratin 20 and epidermal growth factor receptor mRNAs in colorectal cancer tissue samples, HT-29 colorectal cancer cells and colorectal cancer patient peripheral blood samples. A: Detection of carcinoembryonic antigen (CEA), cytokeratin 20 (CK20) and epidermal growth factor receptor (EGFR) mRNA in pairs of colorectal cancer (CRC) and normal adjacent tissue samples. Lane 0 = molecular weight marker (100 bp); lane 1 = normal tissue; lane 2 = CRC tissue; B: Assessment of the sensitivity of the reverse transcription polymerase chain reaction (RT-PCR) detections for CEA, CK20 and EGFR mRNA. Lane 0 = molecular weight marker (100 bp); lane 1 = 10^5 HT-29 cells in 3 mL of normal blood; lane 2 = 10^4 HT-29 cells in 3 mL of normal blood; lane 3 = 10^3 HT-29 cells in 3 mL of normal blood; lane 4 = 10^2 HT-29 cells in 3 mL of normal blood; lane 5 = 10 HT-29 cells in 3 mL of normal blood; lane 6 = 1 HT-29 cell in 3 mL of normal blood; lane 7 = normal blood; C: Assessment of the sensitivity of the multiplex RT-PCR detections for CEA (131 bp), CK20 (371 bp) and EGFR (474 bp) mRNA. Lane 0 = molecular weight marker (100 bp); lane 1 = 10^5 HT-29 cells in 3 mL of normal blood; lane 2 = 10^4 HT-29 cells in 3 mL of normal blood; lane 3 = 10^3 HT-29 cells in 3 mL of normal blood; lane 4 = 10^2 HT-29 cells in 3 mL of normal blood; lane 5 = 10 HT-29 cells in 3 mL of normal blood; lane 6 = 1 HT-29 cell in 3 mL of normal blood; lane 7 = normal blood; D: An example of multiplex RT-PCR-based detection pattern of tumor marker transcripts in the peripheral blood samples of CRC patients. Left: lane 0 = molecular weight marker (100 bp); lane 1 = patient sample positive for CEA (131 bp) and CK20 (371 bp) mRNA; lane 2 = patient sample positive for CEA (131 bp) mRNA; lane 3 = patient sample positive for CEA (131 bp), CK20 (371 bp) and EGFR (474 bp) mRNA; lane 4 = patient sample negative for all markers. Right: lane 0 = molecular weight marker (100 bp); lanes 1-4 = amplification of β -actin (172 bp) cDNA of the patient samples presented in the left side of this panel.

confirmed in pairs of CRC and normal adjacent tissue samples, spiking experiments with HT-29 cells were conducted for establishing the sensitivity of the assay when each marker was run independently (Figure 1). The assay conditions were then accordingly normalized so as to allow the reproducible detection of 10 HT-29 cells in 3 mL of normal blood for all 3 markers examined by multiplex PCR reaction (Figure 1). This cut-off limit has been shown to be of clinical significance in our studies with prostate cancer patients^[41-43]. The detection of each marker both in HT-29 cells and in tissue samples (Figure 1, Panel A) was followed by digestion of the PCR product using restriction enzymes (initial development, data not shown). An example of various detection patterns of CEA, CK20 and EGFR transcripts is presented in panel D of Figure 1.

Out of the 40 healthy peripheral blood samples that were examined, 3 were positive for CEA transcripts, resulting in a specificity percentage of 92.5%. We were unable to correlate this finding with any particular clinical information on file of these volunteers. However, both CK20 and EGFR transcripts were absent from the analy-

sis of healthy samples (specificity 100%). CRC patient characteristics are presented in Table 2.

Cox regression analysis was performed by grouping CRC patients according to the number of detected transcripts using our assay, with the aim of comparing the clinical significance of such detection patterns in CRC patients. Six groups of CRC patients were defined: group 0: no marker expression; group 1: positive only for CEA; group 2: positive for CEA and CK20; group 3: positive for all three markers; group 4: patients of groups 1 and 2 and group 5: patients of groups 2 and 3. Disease stage was found to be an independent prognostic factor for survival when comparisons were performed between group 1 and group 2 ($P = 0.005$), between group 2 and group 3 ($P = 0.005$), between group 3 and group 4 ($P = 0.003$) as well as between group 1 and group 5 ($P = 0.002$). When group 1 and group 3 were compared, tumor size was found to correlate significantly with survival ($P = 0.040$); however, the analysis showed a suggestive prognostic significance of other factors, such as lymph node involvement ($P = 0.088$), stage ($P = 0.066$), sex ($P = 0.062$) and the positivity for all transcripts detection ($P = 0.060$). Cox regression

Table 2 Clinical and pathological characteristics of the colorectal cancer patients enrolled in the study

	No. of cases
Total cases	88
Sex	56
Male	32
Female	
Stage (Astler-Coller)	
A	4
B	26
C	27
D	31
Lymph node metastasis	
No	34
Yes	54
Surgical intervention	
Resection	83
No intervention	5
Distant metastasis	
No	57
Yes (liver/lungs/both)	24/2/5
Age (yr), median (min-max)	69 (43-88)
Tumor size (cm), median (min-max)	4.0 (1.0-11.0)

analysis could not be performed for the comparison of group 0 with the other groups, since all 4 patients with negative detection for all 3 markers were still alive at the time of analysis.

Our analysis revealed that 84 of 88 CRC patients (95.5%) were positive for CEA transcripts; 69 of 88 (78.4%) were positive for CK20 transcripts and 17 of 88 (19.3%) were positive for EGFR transcripts. In particular, 3 of 4 (75%) stage A; 23 of 26 (88.5%) stage B; 27 of 27 (100%) stage C and 31 of 31 (100%) stage D patients were positive for CEA transcripts. In addition, 1 of 4 (25%) stage A, 18 of 26 (69.2%) stage B, 21 of 27 (77.8%) stage C and 29 of 31 (93.5%) stage D CRC patients tested positive for CK20 transcripts. The EGFR transcripts were detected in 17 of 88 (19.3%) patients: in 2 of 26 (7.7%) stage B; in 4 of 27 (14.8%) stage C and in 11 of 31 (35.5%) stage D. No EGFR transcripts were detected in stage A CRC patients. The correlation of PCR detections to disease stage are presented in Table 3.

We documented that 84 CRC patients (95.5%) were positive by multiplex RT-PCR for at least one transcript (CEA); 69 (78.4%) were positive for at least two transcripts (CEA plus CK20), whereas 17 (19.3%) were positive for all 3 transcripts. Four (4.5%) patients showed no transcript detection. The association between clinical and pathological characteristics of patients with multiplex PCR-based detection of tumor markers was analyzed using Spearman's correlation (Table 4). This analysis revealed that any of the 3 transcript detections was positively correlated with Astler-Coller stage of the disease, when examined singly (CEA: Spearman's $\rho = 0.264$, $P = 0.013$; CK20: Spearman's $\rho = 0.306$, $P = 0.004$; EGFR: Spearman's $\rho = 0.305$, $P = 0.004$). In addition, positive detection of CK20 and CEA transcripts was positively correlated with serum CEA levels (CK20: Spearman's $\rho = 0.285$, $P = 0.014$; CEA:

Table 3 Correlation of the number of multiplex reverse transcription polymerase chain reaction positive detections in each blood sample with disease stage in colorectal cancer patients *n* (%)

CRC patients (<i>n</i> = 88)	No. of positive marker detections in each blood sample			
	0	1	2	3
Stage A (<i>n</i> = 4)	1 (25)	2 (50)	1 (25)	0 (0)
Stage B (<i>n</i> = 26)	3 (11.5)	5 (19.2)	16 (61.5)	2 (7.7)
B1 (<i>n</i> = 9)	1 (11.1)	1 (11.1)	7 (77.7)	0 (0)
B2 (<i>n</i> = 17)	2 (11.8)	4 (23.5)	9 (52.9)	2 (11.8)
Stage C (<i>n</i> = 27)	0 (0)	6 (22.2)	17 (63)	4 (14.8)
C1 (<i>n</i> = 5)	0 (0)	1 (20)	3 (60)	1 (20)
C2 (<i>n</i> = 22)	0 (0)	5 (22.7)	14 (63.6)	3 (13.6)
Stage D (<i>n</i> = 31)	0 (0)	2 (6.5)	18 (58.1)	11 (35.5)

Disease staging according to the modified Astler-Coller classification. A positive correlation was revealed using Spearman's test (Spearman's $\rho = 0.396$, $P < 0.001$). CRC: Colorectal cancer.

Spearman's $\rho = 0.228$, $P = 0.050$). Furthermore, a positive correlation was evident between positive detection of the three marker transcript panel and Astler-Coller stage (Spearman's $\rho = 0.396$, $P < 0.001$), as well as serum CEA levels (Spearman's $\rho = 0.253$, $P = 0.029$). Moreover, a suggestive (marginal) association was depicted when the positivity for all 3 transcript detections was analyzed *vs* lymph node involvement (Spearman's $\rho = 0.216$, $P = 0.055$) (Table 4).

Interestingly, all CRC patients who tested negative for all 3 tumor transcripts were alive at the time of verification. Of 15 patients who tested positive only for CEA, 14 were alive (93.3%) (follow-up from 9 to 26 mo). Thirty seven of 52 (71.2%) patients who tested positive for both CEA and CK20 were alive while 15 of them (28.8%) had died (follow-up from 1 to 28 mo). However, 10 of 17 patients who tested positive for all 3 transcripts had died (58.8%) and only 7 of them (41.2%) were alive (follow-up from 1 to 23 mo) at the time of analysis.

Kaplan-Meier plots comparing overall survival rates of groups 1, 2, 3, 4 and 5 are shown in Figure 2. Using log-rank test, such analysis revealed statistically significant differences between survival rates of CRC patient groups with different multiplex RT-PCR detection patterns. When patients with positive detection for only one marker (group 1) were compared to those positive for all three markers (group 3), a statistically significant difference in survival rates was observed ($P = 0.002$). Similarly, the comparison between the patient group with positive detections for two markers (group 2) and positive detections for all 3 markers (group 3) revealed significant differences in survival rates ($P = 0.007$). Likewise, significant survival differences were documented when survival of group 4 (groups 1 and 2) was compared to survival of group 3 ($P = 0.001$). In addition, significant differences in the survival of CRC patients were also found when group 1 was compared with group 5 (at least positive for 2 transcripts) ($P = 0.041$). No statistical significance was observed when group 1 was compared to group 2 ($P = 0.116$).

Table 4 Analysis of the clinical and pathological characteristics in relation to the detection pattern of circulating tumor cells using the carcinoembryonic antigen, cytokeratin 20 and epidermal growth factor receptor multiplex assay *n* (%)

Parameter	No. of positive markers in each blood sample				P-value
	0	1	2	3	
Age (yr)					
< 69	1 (2.4)	7 (17.1)	26 (63.4)	7 (17.1)	
≥ 69	3 (6.4)	8 (17)	26 (55.3)	10 (21.3)	0.963
Sex					
Male	3 (5.4)	8 (14.3)	32 (57.1)	13 (23.2)	
Female	1 (3.1)	7 (21.9)	20 (62.5)	4 (12.5)	0.294
Stage (Astler-Coller)					
A + B	4 (13.3)	7 (23.3)	17 (56.7)	2 (6.7)	
C	0 (0)	6 (22.2)	17 (63)	4 (14.8)	
D	0 (0)	2 (6.5)	18 (58.1)	11 (35.5)	< 0.001
Lymph node involvement ¹					
≤ 3	4 (7.1)	11 (19.6)	35 (62.5)	6 (10.7)	
> 3	0 (0)	4 (16)	14 (56)	7 (28)	0.055
Tumor size (cm) ²					
< 3	2 (10.5)	2 (10.5)	15 (79)	0 (0)	
3-5	1 (2.5)	8 (20)	21 (52.5)	10 (25)	
> 5	1 (4.8)	5 (23.8)	11 (52.4)	4 (19)	0.774
Differentiation ³					
Well + moderate	4 (6.8)	10 (17)	36 (61)	9 (15.2)	
Poor + no	0 (0)	4 (22.2)	10 (55.6)	4 (22.2)	0.560
Serum CEA (ng/mL) ⁴					
< 5	3 (10)	9 (30)	12 (40)	6 (20)	
5-10	0 (0)	1 (7.1)	11 (78.6)	2 (14.3)	
> 10	0 (0)	4 (13.3)	17 (56.7)	9 (30)	0.029

P-values were calculated by Spearman's test. ¹P-value calculation using data from 81 patients (7 missing values); ²P-value calculation using data from 80 patients (8 missing values); ³P-value calculation using data from 77 patients (11 missing values); ⁴P-value calculation using data from 74 patients (14 missing values). CEA: Carcinoembryonic antigen.




Figure 2 Kaplan-Meier analysis comparing the overall survival of patient groups as developed according to transcript detection patterns for carcinoembryonic antigen, cytokeratin 20 and epidermal growth factor receptor. Group 1: Carcinoembryonic antigen (CEA) positive; Group 2: Positive for 2 markers (CEA and cytokeratin 20); Group 3: Positive for all markers; Group 4: Combination of groups 1 and 2; Group 5: Combination of groups 2 and 3. Log Rank test P values were as follows: Groups 1 vs 3: *P* = 0.002; Groups 2 vs 3: *P* = 0.007; Groups 4 vs 3: *P* = 0.001; Groups 1 vs 5: *P* = 0.041; Groups 1 vs 2: *P* = 0.116.

DISCUSSION

The advantages of multi-marker use for CTC detection in CRC patients have been previously described^[5,44-46]. Several studies have shown that the use of more than one marker independently increases the sensitivity and the specificity of CTC detection which correlates with disease stage in CRC patients^[47-51]. However, the application of separate PCR reactions for each marker can be impractical, time-consuming and costly. Conversely, the implementation of multiplex RT-PCR which allows the examination of multiple marker expression in a single reaction could be advantageous. The employment of multiplex RT-PCR on peripheral blood samples represents an easily applied, non-invasive technique for the detection of CTCs in cancer patients^[52].

The aim of the present study was to develop first and then to test the clinical significance of a multiplex RT-PCR-based detection of three markers (CEA, CK20 and EGFR) in CRC patients. Since we used a short follow-up period, our main analysis was based on overall survival and not on progression-free survival.

Our multiplex PCR-based detections of CEA, CK20 and EGFR transcripts were characterized by very good specificity, since none of the 40 healthy donor samples was found positive for the expression of CK20 or EGFR mRNA and only 3 control samples tested positive for CEA transcripts. This revealed that our assay was of higher specificity than that of previous studies^[30,31,53,54]. The observed false positive results in control subjects could be attributed to illegitimate transcription of CEA in mononuclear blood cells. Indeed, it has been reported that CEA mRNA is detected in peripheral blood CD34+ progenitor cells^[55]. Based on our data, CEA detection was the most sensitive (expressed in 95.5% of the CRC patients); the positivity rate was higher than that observed by Guadagni *et al.*^[22] or by Ferroni *et al.*^[56]. This, however, may be due to clinicopathological characteristics of the enrolled patients in this study and our experimental setting. Moreover, our data suggested that EGFR is possibly a marker for advanced stage in CRC (expressed in 19.3% of the patients and mostly in advanced disease). CK20 detection corresponded to a detection rate of 78.4%, higher than that reported previously by other groups^[15,31,57,58]. Again, these detection rate discrepancies among studies using the same mRNA markers can be attributed to patient characteristics, as well as to the particular experimental conditions used by each research group.

Herein, our results revealed that the increasing number of the transcripts detected in this experimental setting could distinguish certain patient groups having significantly different overall survival. However, the detection of 1 (CEA) *vs* the detection of 2 markers (CEA plus CK20) did not show any statistically significant difference in overall survival ($P = 0.116$), which may be attributed to the short follow-up period. Notably, none of the CRC patients who tested negative for all 3 markers died during follow-up. These results are in concert with the results of Wang *et al.*^[48], who examined a membrane array-based de-

tection of 4 mRNA markers, including CEA and CK20, in 157 CRC patients and found that the positive detection of all 4 markers (human telomerase reverse transcriptase, CK19, CK20, and CEA) was associated with poor overall survival. Similar results were reported by Uen *et al.*^[47], analyzing the detection of the same transcripts with progression-free survival in CRC patients.

In addition, Spearman's test revealed a positive correlation of positive detection for all 3 transcripts in our assay with higher disease stage and preoperative serum CEA levels. Furthermore, a suggestive correlation was also evident between positive detection of transcripts and higher level of lymph node involvement, suggesting that the higher number of tumor markers detected as positive by multiplex PCR assay is associated with higher levels of serum CEA and a larger amount of lymph node involvement, which are considered as indicators of advanced disease. This is in concert with the findings of Yeh *et al.*^[49]. Other studies have also examined the detection of CEA, CK20 or EGFR transcripts, however, using single PCR-based assays and reported that the higher number of positive detections correlated with disease stage^[18,22,27,59] and serum CEA levels^[38,60,61] or the presence of lymph node metastasis^[58,62,63].

Herein, the increased number of positive multiplex PCR-based detections in each blood sample correlated with overall survival in CRC patients. Although the detection of the three marker panel was not found to be an independent prognostic factor of overall survival using Cox regression analysis, the log-rank test documented significant differences in overall survival rates among the patient groups formed according to the number of positive detections in each blood sample of CRC patients.

Nevertheless, our data suggested that our multiplex RT-PCR assay can provide useful information concerning CRC stage and overall survival. The combination of the mRNA markers in a single reaction could be of clinical value in the early detection of disseminated disease and monitoring of CRC patients, as it has been documented in other malignancies^[5,41-45,64,65]. Future larger-scale studies and longer follow-up surveys would prove the clinical significance and prognostic importance of multiplex PCR-based detection of CTCs using CEA, CK20 and EGFR in CRC patients.

COMMENTS

Background

Colorectal cancer (CRC) is one of the most frequently diagnosed malignancies in both men and women. Overall survival is associated with the disease stage at the time of diagnosis, suggesting that early detection of disseminated disease may be of great significance. Detection of disseminated tumor cells in the peripheral blood of CRC patients could be promising for the early detection of disseminated disease and monitoring of CRC patients.

Research frontiers

Various techniques have been used for the detection of circulating tumor cells (CTCs) derived by solid tumors; among those, reverse transcription polymerase chain reaction (RT-PCR)-based methods have allowed the sensitive detection of CTCs in peripheral blood samples. Among several molecular markers, cytokeratin 20 (CK20), carcinoembryonic antigen (CEA) and epidermal growth fac-

tor receptor (EGFR) are those more frequently used for CTC detection in CRC using PCR-based methods.

Innovations and breakthroughs

Several studies have shown that the use of more than one marker independently increases the sensitivity and the specificity of the CTC detection in CRC patients. However, the application of separate PCR reactions for each marker can be impractical, while the implementation of multiplex RT-PCR allows the examination of multiple marker expression in a single reaction. The employment of multiplex RT-PCR in peripheral blood samples represents an easily applied, non-invasive technique for the detection of CTCs in cancer patients. The results showed that multiplex RT-PCR assay can provide useful information concerning CRC stage and overall survival.

Applications

The combination of mRNA markers in a single reaction could be of clinical value in the early detection of disseminated disease and monitoring of CRC patients. Future larger-scale studies and longer follow-up surveys would prove the clinical significance and prognostic importance of multiplex PCR-based detection of CTCs using CEA, CK20 and EGFR mRNA in CRC patients.

Terminology

CK20 is a member of the intermediate filament protein family and a prominent component of intestinal epithelium. CEA is a high molecular weight glycoprotein that plays a role in CRC metastasis. EGFR exerts control over normal cell growth and cancer pathogenesis in humans. Their mRNAs can be used as markers for the identification of CTCs in peripheral blood samples of CRC patients.

Peer review

This is a well written and produced paper with an important message. This original paper uses multiplex PCR assay for CK20, CEA and EGFR on blood samples to give information about CRC stage and prognosis. The authors have only studied small numbers of cases but the initial results are very encouraging.

REFERENCES

- 1 **Ferlay J**, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. *Ann Oncol* 2007; **18**: 581-592
- 2 **Mutch MG**. Molecular profiling and risk stratification of adenocarcinoma of the colon. *J Surg Oncol* 2007; **96**: 693-703
- 3 **O'Connell JB**, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. *J Natl Cancer Inst* 2004; **96**: 1420-1425
- 4 **Ghossein RA**, Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. *Eur J Cancer* 2000; **36**: 1681-1694
- 5 **Tsouma A**, Aggeli C, Pissimissis N, Lembessis P, Zografos GN, Koutsilieris M. Circulating tumor cells in colorectal cancer: detection methods and clinical significance. *Anticancer Res* 2008; **28**: 3945-3960
- 6 **Khair G**, Monson JR, Greenman J. Epithelial molecular markers in the peripheral blood of patients with colorectal cancer. *Dis Colon Rectum* 2007; **50**: 1188-1203
- 7 **Zieglschmid V**, Hollmann C, Böcher O. Detection of disseminated tumor cells in peripheral blood. *Crit Rev Clin Lab Sci* 2005; **42**: 155-196
- 8 **Moll R**, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. *J Cell Biol* 1990; **111**: 567-580
- 9 **Moll R**, Löwe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. *Am J Pathol* 1992; **140**: 427-447
- 10 **Moll R**, Zimbelmann R, Goldschmidt MD, Keith M, Laufer J, Kasper M, Koch PJ, Franke WW. The human gene encoding cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas. *Differentiation* 1993; **53**: 75-93
- 11 **Fletcher RH**. Carcinoembryonic antigen. *Ann Intern Med* 1986; **104**: 66-73
- 12 **Berman JM**, Cheung RJ, Weinberg DS. Surveillance after colorectal cancer resection. *Lancet* 2000; **355**: 395-399
- 13 **Arnaud JP**, Koehl C, Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. *Dis Colon Rectum* 1980; **23**: 141-144
- 14 **Harrison LE**, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. *J Am Coll Surg* 1997; **185**: 55-59
- 15 **Zhang XW**, Yang HY, Fan P, Yang L, Chen GY. Detection of micrometastasis in peripheral blood by multi-sampling in patients with colorectal cancer. *World J Gastroenterol* 2005; **11**: 436-438
- 16 **Weitz J**, Kienle P, Lacroix J, Willeke F, Benner A, Lehnert T, Herfarth C, von Knebel Doeberitz M. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. *Clin Cancer Res* 1998; **4**: 343-348
- 17 **Fujita S**, Kudo N, Akasu T, Moriya Y. Detection of cytokeratin 19 and 20 mRNA in peripheral and mesenteric blood from colorectal cancer patients and their prognosis. *Int J Colorectal Dis* 2001; **16**: 141-146
- 18 **Kienle P**, Koch M, Autschbach F, Benner A, Treiber M, Wannenmacher M, von Knebel Doeberitz M, Büchler M, Herfarth C, Weitz J. Decreased detection rate of disseminated tumor cells of rectal cancer patients after preoperative chemoradiation: a first step towards a molecular surrogate marker for neoadjuvant treatment in colorectal cancer. *Ann Surg* 2003; **238**: 324-330; discussion 330-331
- 19 **Yamaguchi K**, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. *Ann Surg* 2000; **232**: 58-65
- 20 **Sadahiro S**, Suzuki T, Maeda Y, Yurimoto S, Yasuda S, Makuuchi H, Kamijo A, Murayama C. Detection of carcinoembryonic antigen messenger RNA-expressing cells in peripheral blood 7 days after curative surgery is a novel prognostic factor in colorectal cancer. *Ann Surg Oncol* 2007; **14**: 1092-1098
- 21 **Noh YH**, Kim JA, Lim GR, Ro YT, Koo JH, Lee YS, Han DS, Park HK, Ahn MJ. Detection of circulating tumor cells in patients with gastrointestinal tract cancer using RT-PCR and its clinical implications. *Exp Mol Med* 2001; **33**: 8-14
- 22 **Guadagni F**, Kantor J, Aloe S, Carone MD, Spila A, D'Alessandro R, Abbolito MR, Cosimelli M, Graziano F, Carboni F, Carlini S, Perri P, Sciarretta F, Greiner JW, Kashmiri SV, Steinberg SM, Roselli M, Schlom J. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers. *Cancer Res* 2001; **61**: 2523-2532
- 23 **Hildebrandt M**, Mapara MY, Körner JJ, Bargou RC, Moldenhauer G, Dörken B. Reverse transcriptase-polymerase chain reaction (RT-PCR)-controlled immunomagnetic purging of breast cancer cells using the magnetic cell separation (MACS) system: a sensitive method for monitoring purging efficiency. *Exp Hematol* 1997; **25**: 57-65
- 24 **Leitzel K**, Lieu B, Curley E, Smith J, Chinchilli V, Rychlik W, Lipton A. Detection of cancer cells in peripheral blood of breast cancer patients using reverse transcription-polymerase chain reaction for epidermal growth factor receptor. *Clin Cancer Res* 1998; **4**: 3037-3043
- 25 **Gradilone A**, Gazzaniga P, Silvestri I, Gandini O, Trasatti L, Lauro S, Frati L, Aglianò AM. Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease. *Oncol Rep* 2003; **10**: 217-222
- 26 **Gazzaniga P**, Nofroni I, Gandini O, Silvestri I, Frati L, Aglianò AM, Gradilone A. Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in blad-

- der and colon cancer. *Oncol Rep* 2005; **14**: 1199-1202
- 27 **Giacomelli L**, Gianni W, Belfiore C, Gandini O, Repetto L, Filippini A, Frati L, Aglianò AM, Gazzaniga P. Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. *Clin Cancer Res* 2003; **9**: 2678-2682
 - 28 **Gazzaniga P**, Gandini O, Giuliani L, Magnanti M, Gradilone A, Silvestri I, Gianni W, Gallucci M, Frati L, Aglianò AM. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. *Clin Cancer Res* 2001; **7**: 577-583
 - 29 **Clarke LE**, Leitzel K, Smith J, Ali SM, Lipton A. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR. *Int J Oncol* 2003; **22**: 425-430
 - 30 **De Luca A**, Pignata S, Casamassimi A, D'Antonio A, Gridelli C, Rossi A, Cremona F, Parisi V, De Matteis A, Normanno N. Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. *Clin Cancer Res* 2000; **6**: 1439-1444
 - 31 **Wyld DK**, Selby P, Perren TJ, Jonas SK, Allen-Mersh TG, Wheeldon J, Burchill SA. Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. *Int J Cancer* 1998; **79**: 288-293
 - 32 **Friederichs J**, Gertler R, Rosenberg R, Nahrig J, Führer K, Holzmann B, Dittler HJ, Dahm M, Thorban S, Nekarda H, Siewert JR. Prognostic impact of CK-20-positive cells in peripheral venous blood of patients with gastrointestinal carcinoma. *World J Surg* 2005; **29**: 422-428
 - 33 **Giribaldi G**, Procida S, Ulliers D, Mannu F, Volpato R, Mandili G, Fanchini L, Bertetto O, Fronda G, Simula L, Rimini E, Cherchi G, Bonello L, Maule MM, Turrini F. Specific detection of cytokeratin 20-positive cells in blood of colorectal and breast cancer patients by a high sensitivity real-time reverse transcriptase-polymerase chain reaction method. *J Mol Diagn* 2006; **8**: 105-112
 - 34 **Koch M**, Kienle P, Sauer P, Willeke F, Buhl K, Benner A, Lehner T, Herfarth C, von Knebel Doeberitz M, Weitz J. Hematogenous tumor cell dissemination during colonoscopy for colorectal cancer. *Surg Endosc* 2004; **18**: 587-591
 - 35 **Molnar B**, Ladanyi A, Tanko L, Sréter L, Tulassay Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. *Clin Cancer Res* 2001; **7**: 4080-4085
 - 36 **Wharton RQ**, Jonas SK, Glover C, Khan ZA, Klokouzas A, Quinn H, Henry M, Allen-Mersh TG. Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. *Clin Cancer Res* 1999; **5**: 4158-4163
 - 37 **Lankiewicz S**, Rother E, Zimmermann S, Hollmann C, Korangy F, Greten TF. Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. *Cell Oncol* 2008; **30**: 463-471
 - 38 **Silva JM**, Rodriguez R, Garcia JM, Muñoz C, Silva J, Dominguez G, Provencio M, España P, Bonilla F. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. *Gut* 2002; **50**: 530-534
 - 39 **Bostick PJ**, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, Hoon DS. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. *J Clin Oncol* 1998; **16**: 2632-2640
 - 40 **Mapara MY**, Körner IJ, Hildebrandt M, Bargou R, Krahl D, Reichardt P, Dörken B. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. *Blood* 1997; **89**: 337-344
 - 41 **Lembessis P**, Msaouel P, Halapas A, Sourla A, Panteleakou Z, Pissimissis N, Milathianakis C, Bogdanos J, Papaioannou A, Maragoudakis E, Dardoufas C, Dimopoulos T, Koutsilieris M. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. *Clin Chem Lab Med* 2007; **45**: 1488-1494
 - 42 **Koutsilieris M**, Lembessis P, Luu-The V, Sourla A. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. *Clin Exp Metastasis* 1999; **17**: 823-830
 - 43 **Mitsiades CS**, Lembessis P, Sourla A, Milathianakis C, Tsin-tavis A, Koutsilieris M. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. *Clin Exp Metastasis* 2004; **21**: 495-505
 - 44 **Nezos A**, Pissimissis N, Lembessis P, Sourla A, Dimopoulos P, Dimopoulos T, Tzelepis K, Koutsilieris M. Detection of circulating tumor cells in bladder cancer patients. *Cancer Treat Rev* 2009; **35**: 272-279
 - 45 **Panteleakou Z**, Lembessis P, Sourla A, Pissimissis N, Polyzos A, Deliveliotis C, Koutsilieris M. Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. *Mol Med* 2009; **15**: 101-114
 - 46 **Nezos A**, Lembessis P, Sourla A, Pissimissis N, Gogas H, Koutsilieris M. Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. *Clin Chem Lab Med* 2009; **47**: 1-11
 - 47 **Uen YH**, Lin SR, Wu DC, Su YC, Wu JY, Cheng TL, Chi CW, Wang JY. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. *Ann Surg* 2007; **246**: 1040-1046
 - 48 **Wang JY**, Lin SR, Wu DC, Lu CY, Yu FJ, Hsieh JS, Cheng TL, Koay LB, Uen YH. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. *Clin Cancer Res* 2007; **13**: 2406-2413
 - 49 **Yeh CS**, Wang JY, Wu CH, Chong IW, Chung FY, Wang YH, Yu YP, Lin SR. Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel. *Int J Oncol* 2006; **28**: 411-420
 - 50 **Conzelmann M**, Linnemann U, Berger MR. Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use? *Int J Colorectal Dis* 2005; **20**: 137-146
 - 51 **Gervasoni A**, Monasterio Muñoz RM, Wengler GS, Rizzi A, Zaniboni A, Parolini O. Molecular signature detection of circulating tumor cells using a panel of selected genes. *Cancer Lett* 2008; **263**: 267-279
 - 52 **Taback B**, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano AE, Hoon DS. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. *Cancer Res* 2001; **61**: 8845-8850
 - 53 **Wong IH**, Yeo W, Chan AT, Johnson PJ. Quantitative relationship of the circulating tumor burden assessed by reverse transcription-polymerase chain reaction for cytokeratin 19 mRNA in peripheral blood of colorectal cancer patients with Dukes' stage, serum carcinoembryonic antigen level and tumor progression. *Cancer Lett* 2001; **162**: 65-73
 - 54 **Vlems FA**, Diepstra JH, Cornelissen IM, Ruers TJ, Ligtenberg MJ, Punt CJ, van Krieken JH, Wobbes T, van Muijen GN. Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with

- colorectal cancer: expression in controls and downregulation in tumour tissue. *Mol Pathol* 2002; **55**: 156-163
- 55 **Fava TA**, Desnoyers R, Schulz S, Park J, Weinberg D, Mitchell E, Waldman SA. Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood. *J Clin Oncol* 2001; **19**: 3951-3959
- 56 **Ferroni P**, Roselli M, Spila A, D'Alessandro R, Portarena I, Mariotti S, Palmirota R, Buonomo O, Petrella G, Guadagni F. Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients. *Cancer* 2010; **116**: 2913-2921
- 57 **Katsumata K**, Sumi T, Mori Y, Hisada M, Tsuchida A, Aoki T. Detection and evaluation of epithelial cells in the blood of colon cancer patients using RT-PCR. *Int J Clin Oncol* 2006; **11**: 385-389
- 58 **Dandachi N**, Balic M, Stanzer S, Halm M, Resel M, Hinterleitner TA, Samonigg H, Bauernhofer T. Critical evaluation of real-time reverse transcriptase-polymerase chain reaction for the quantitative detection of cytokeratin 20 mRNA in colorectal cancer patients. *J Mol Diagn* 2005; **7**: 631-637
- 59 **Shen C**, Hu L, Xia L, Li Y. Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients. *Jpn J Clin Oncol* 2008; **38**: 770-776
- 60 **Friederichs J**, Gertler R, Rosenberg R, Dahm M, Nekarda H, Holzmann B, Siewert JR. Correlation of CK-20-positive cells in peripheral venous blood with serum CEA levels in patients with colorectal carcinoma. *World J Surg* 2007; **31**: 2329-2334
- 61 **Vlems FA**, Diepstra JH, Punt CJ, Ligtenberg MJ, Cornelissen IM, van Krieken JH, Wobbes T, van Muijen GN, Ruers TJ. Detection of disseminated tumour cells in blood and bone marrow samples of patients undergoing hepatic resection for metastasis of colorectal cancer. *Br J Surg* 2003; **90**: 989-995
- 62 **Iinuma H**, Okinaga K, Egami H, Mimori K, Hayashi N, Nishida K, Adachi M, Mori M, Sasako M. Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. *Int J Oncol* 2006; **28**: 297-306
- 63 **Guo J**, Xiao B, Zhang X, Jin Z, Chen J, Qin L, Mao X, Shen G, Chen H, Liu Z. Combined use of positive and negative immunomagnetic isolation followed by real-time RT-PCR for detection of the circulating tumor cells in patients with colorectal cancers. *J Mol Med* 2004; **82**: 768-774
- 64 **Mitropapas G**, Nezos A, Halapas A, Pissimissis N, Lembessis P, Sourla A, Vassilopoulos P, Koutsilieris M. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics. *Clin Chem Lab Med* 2006; **44**: 1403-1409
- 65 **Karavitaki N**, Lembessis P, Tzanela M, Vlassopoulou V, Thalassinou N, Koutsilieris M. Molecular staging using qualitative RT-PCR analysis detecting thyroglobulin mRNA in the peripheral blood of patients with differentiated thyroid cancer after therapy. *Anticancer Res* 2005; **25**: 3135-3142

S- Editor Tian L L- Editor O'Neill M E- Editor Zheng XM